 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN- 2018 ) Page 1 of 70  Study Protocol  LUD2015-0 06 US-IND# exempt  
BMS C A209-412 
Amendment 5 FINAL  12-JUN-2018  
 
Protocol Title  
A Pilot (Phase 1) Study  to Evaluate the Safety and Efficacy of Combin ation Checkpoint Blockade 
(Ipilimumab and Nivolumab) Plus  External Beam Radiotherapy  in Subjects with Stage IV 
Melanoma  
 
Objectives and Synopsis  
This is an open -label, multicenter pilot Phase 1 study of the checkpoint antibodies ipilimumab and 
nivolumab  in combination with radiotherapy  (RT) in 18 subjects with unresectable stage IV melanoma . 
All subject s will receive concurrent  ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 
doses, followed by nivolumab monotherapy ( 240 mg every 2 weeks ). Note: per Amendment 5, 
nivolumab monotherapy continuing after Week 18  may be given as 480 mg every 4 weeks .  
Radiother apy will be initiated after the first dose and before th e second dose of immunotherapy.  
There will be 2 cohorts in the study. Subject s in Cohort A will initially receive a conventional total  
palliative dose of 30 Gy delivered over 2  weeks in 10  fractions of 3  Gy each . Once 9 subject s have been 
accrued to Cohort  A and completed  the concurrent ipilimumab  and nivolumab  therapy, if ≤  7 subject s 
have Grade 3 or 4 drug- or radiation -related adverse events, the safety of Cohort  A will be de emed 
acceptable and additional subject s will be accrued to  Cohort B  (see exception in Section 3.1 , i.e., 
asymptomatic amylase and lipase abnormalities are not included) . Subjects in Cohort B  will receive the 
high -dose hypofractionated RT for which t reatment of a target lesion will comprise a total palliative 
dose of 27  Gy delivered over 2 weeks in 3 fractions of 9  Gy each.  
The primary objective is the assessment of safety according to the National Cancer Institute (NCI) 
Common Terminology Criteria for Advers e Events (CTCAE), Version 4.03. 
The secondary objectives  are to evaluate: (1) objective response rate (ORR) at Weeks 12 and 18, (2) 
disease control rate (DCR) at Weeks 12 and 18, (3) duration  of response, (4)  progression -free survival 
(PFS), and (5) overall survival (OS) . 
The exploratory objectives  are to perform correlative studies investigating the immunological effects of 
ipilimumab and nivolumab with RT.  
Assessment methods include  the NCI  CTCAE  (Version 4.03 ) for safety  and the modified Response 
Evaluation Criteria for Soli d Tumors (RECIST) 1.1 (primary) and  immune- related RECIST (irR ECIST; 
secondary)  for clinical efficacy . 
 
Sponsor:  Ludwig Institute for Cancer Research,  
New York, NY  
 
 
 
 
 
 
Sponsor representative Signature & Date  Study Chair:   Michael Postow, MD, Memorial Sloan 
Kettering Cancer Center (MSKCC)  
  
 
 
 
 
Study Chair  Signature & Date  
 
Confidentiality Statement  
The confidential and proprietary information in this document is owned by the Ludwig Institute for Cancer Research and 
provided to you as an Investigator, potential Investigator, or consultant, for review by you, your staff, and applicable inst itutional 
review board(s). The information cannot be used, or divulged to any third party or published without the written consent of the 
Ludwig Institut e for Cancer Research, except to the extent necessary to obtain informed consent from those persons to whom 
study m edication may be administered. Any misappropriation of this information is prohibited by law.  

 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 2 of 70 Table of Content s 
1 Background  ............................................................................................................................. 5 
1.1 Melanoma  ....................................................................................................................... 5 
1.2 Ipilimumab  ....................................................................................................................... 5 
1.3 Nivolumab  ....................................................................................................................... 6 
1.4 Radiotherapy  for Melanoma ........................................................................................... 6 
2 Study Rationale  ....................................................................................................................... 8 
2.1 Preclinical Rationale for Combining Radiotherapy and Checkpoint Blockade  ................ 8 
2.2 Clinical Rationale for Combining Radiotherapy and Checkpoint Blockade  ..................... 9 
3 Experimental Plan  ................................................................................................................. 10 
3.1 Study Design  .................................................................................................................. 10 
3.1.1  Study Phase  ........................................................................................................... 10 
3.1.2  Enrollment/Randomization  ................................................................................... 10 
3.1.3  Blinding/Unblinding  ............................................................................................... 10 
3.1.4 Subject Population .................................................................................................  11 
3.1.5  Number of Sites/Subjects  ...................................................................................... 11 
3.1.6  Sample Size and Statistical Considerations  ........................................................... 11 
3.1.7  Treatment Arms and Treatment Schema  .............................................................. 11 
3.1.8  Dosing Adjustments, Delays, and Discontinuations  .............................................. 12 
3.1.9  Dose -limiting Toxicity  ............................................................................................ 12 
3.1.10  Subject Withdrawal from Treatment or from Study  ............................................. 12 
3.1.11  Subject Evaluability and Subject Replacement  ..................................................... 13 
3.1.12  Optional Study Treatment Extension  .................................................................... 13 
3.1.13  Interim Analysis  ..................................................................................................... 13 
3.1.14  Safety Monitoring and Study S topping Rules  ........................................................ 13 
3.1.15  Duration of Study  .................................................................................................. 14 
3.1.16  On Study and Post -Study Follow -up ...................................................................... 14 
3.2 Study Flowchart  ............................................................................................................. 15 
4 Study Objectives & Endpoints  .............................................................................................. 18 
4.1 Safety and Tolerability  ................................................................................................... 18 
4.1.1  Endpoints & Assessment Methods  ........................................................................ 18 
4.1.2  Subject Evaluation & Statistics  .............................................................................. 18 
4.2 Clinical Efficacy  .............................................................................................................. 19 
4.2.1  Endpoints & Assessment Methods  ........................................................................ 19 
4.2.1.1  Tumor Response and Overall Response Rate  ................................................ 19 
4.2.1.2  Disease Control Rate  ..................................................................................... 19 
4.2.1.3  Duration of Response  .................................................................................... 19 
4.2.1.4  Progression -free Survival  ............................................................................... 20 
4.2.1.5  Overall Survival  .............................................................................................. 20 
4.2.2  Subject Evaluation & Statistics  .............................................................................. 20 
4.3 Antitumor Immunity  ...................................................................................................... 20 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 3 of 70 4.3.1  Endpoints & Assessment Methods  ........................................................................ 20 
4.4 Additional Exploration of Immune Response  ................................................................ 21 
5 Subject Eligibility  ................................................................................................................... 22 
5.1 Inclusion Criteria  ............................................................................................................ 22 
5.2 Exclusion Criteria  ........................................................................................................... 23 
5.3 Restrictions on Concomitant Therapies  ........................................................................ 25 
5.3.1  Non -Permitted Concomitant Therapies  ................................................................ 25 
5.3.2  Permitted Concomitant Therapies  ........................................................................ 25 
6 Study Drug Preparation and Administration  ........................................................................ 26 
6.1 Ipilimumab and Nivolumab  ........................................................................................... 26 
6.1.1  Nivolumab Storage Conditions & Handling  ........................................................... 26 
6.1.2  Nivolumab Preparation and Administration  ......................................................... 27 
6.1.3  Ipilimumab Storage Conditions & Handling  .......................................................... 28 
6.1.4  Ipilimumab Preparation and Administration  ......................................................... 28 
6.2 Radiotherapy  ................................................................................................................. 29 
6.3 Drug Overdose Management  ........................................................................................ 29 
7 Administrative, Legal & Ethical Requirements  ..................................................................... 30 
7.1 Documentation and Reporting of Adverse Events  ........................................................ 30 
7.1.1  General AE/SAE Definitions per ICH Guidelines  .................................................... 30 
7.1.2  Additional SAE  Definitions for this Study  .............................................................. 31 
7.1.3  Severity of an Adverse Event ................................................................................. 31 
7.1.4  Relationship of Adverse Events to Study Drug  ...................................................... 31 
7.1.5  General Reporting Requirements  .......................................................................... 32 
7.1.6  Expedited Serious Adverse Event (SAE) Reporting Requirements  ........................ 32 
7.1.7  Serious Adverse Event (SAE) Follow- up Requirem ents  ......................................... 33 
7.2 Administrative Sponsor Requirements  ......................................................................... 33 
7.2.1  Study Master Files  .................................................................................................  33 
7.2.2 Case Report Form Data Collection  ........................................................................ 33 
7.2.3  Language  ................................................................................................................ 33 
7.2.4  Monitoring  ............................................................................................................. 34 
7.2.5  Protocol Amendments  ........................................................................................... 34 
7.2.6  Premature Subject Withdrawal  ............................................................................. 34 
7.2.7  Early Trial Termination  .......................................................................................... 34 
7.2.8 Study Drug Shipments & Accountability  ............................................................... 35 
7.3 Regulatory, Legal, & Ethical Requirements  ................................................................... 36 
7.3.1  Good Clinical Practice (GCP), Laws and Regulations  ............................................. 36 
7.3.2  Informed Consent  .................................................................................................. 36 
7.3.3  Institutional Review Board  .................................................................................... 36 
7.3.4  Subject Confidentiality  .......................................................................................... 36 
8 Appendices  ........................................................................................................................... 38 
8.1 Protocol Version History  ................................................................................................ 38 
8.2 Participating Study Sites, Investigators and Staff, Laboratories, and Sponsor 
Information  ............................................................................................................................... 45 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 4 of 70 8.3 Ipilimumab and Nivolumab Dose Delays and Adjustments  .......................................... 46 
8.3.1  Management Algorithms for Adverse Events Associated with Immuno -oncology 
Agents   ............................................................................................................................... 49 
8.4 RECIST 1.1 and irRECIST Guidelines  ............................................................................... 50 
8.5 Recommended Guidelines for Radiation Therapy  ........................................................ 58 
8.5.1  Target selection for radiation therapy  .................................................................. 58 
8.5.2  Treatment position, immobilization, and si mulation  ............................................ 58 
8.5.3  Target delineation  .................................................................................................  59 
8.5.4  Organ at risk dose (OAR) delineation and dose constraints .................................. 60 
8.5.5  Beam selection and geometry, planning technique and treatment delivery  ....... 63 
8.5.6  Radiothe rapy timing and dose fractionation  ........................................................ 63 
8.6 Exploratory Assessment of Correlative Immunologic Research  .................................... 64 
8.7 Abbreviations ................................................................................................................. 65 
9 References  ............................................................................................................................ 67 
 
LIST OF TABLES  
Table 1.  Treatment Schema  .................................................................................................... 11 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 5 of 70 1 Background  
1.1 Melanoma  
The incidence of malignant melanoma is rising and the mo rtality rate is increasing .(1) These 
concerning trends are occurring despite the recent decline in the incidence of several other 
cancer types. Despite this concerning trend, the overall survival (OS) for all patients diagnosed 
with melanoma has improved for early stage tumors because of early detection an d improved 
surgical treatment. Nonetheless, man y patients who undergo curative -intent surgical treatment 
of high -risk disease ultimately recur, and re current and/or metastatic melanoma remains a 
largely fatal disease , with a median s urvival of 3 to 11 month s.(2) 
The only adjuvant treatment approved by the US FDA after resection of high -risk melanoma is 
IFN-α. Unfortunately , treatment with high -dose IFN -α is associated with significant side effects, 
and its ro le in pro longing survival is not clear. One study showed an OS benefit, but this was not 
confirmed in a pooled analysis with longer follow -up.(3, 4) 
Until 2011, dacarbazine and interleukin -2 (IL -2) were the only US FDA approved treat ments for 
metastatic melanoma. Dacarbazine provides an objective tumor response in only 5% to 20% of 
subjects, and these responses are short -lived (median duration of re sponse is 6 months) . 
Dacarbazine has also never been shown to improve OS .(2)  IL-2 was approved by the FDA in 
1998 for treatment of metastatic melanoma . The FDA approval was based on data suggesting a 
16% overall objective response rate with a 6% complete response. However, toxicities of high 
dose IL -2 therapy were severe (e. g., capillary leak, sepsis, and hypotension), and 2% of subjects 
died from such associated adverse event s (AEs). (5)  
Since 2011, many new treatments have been approved for patients with melanoma.   For 
patients with BRAF mutations, the BRAF inhibitors dabrafenib and vemurafenib have led to dramatic results with recent demonstration of an overall survival b enefit of combining the BRAF 
inhibitor, dabrafenib with the MEK inhibitor, trametinib .(6)  Immunotherapy with immune 
checkpoint blocking antibodies has similarly led to remarkable advances in advanced melanoma with 3 currently FDA -approved drugs: Ipilimumab, nivolumab, and pembrolizumab .(7-9) 
1.2 Ipilimumab  
Ipilimumab enhances antitumor immunity by blocking the normally negative regulator of T cell function, cytotoxic T -lymphocyte antigen 4 (CTLA -4) and has demonstrated a survival benefit for 
subject s with advanced melanoma in two Phase 3 trials .(10, 11)  Though ipilimumab can result 
in impressive long -term tumor control ,(12) unfortunately only a subset of patients benefit.  
Responses to ipilimumab are often delayed and may be seen after initial apparent disease progression . The unique pattern of disease response seen in subject s with ipilimumab led to a 
retrospective study an alyzing subject s treated across several Phase 2 trials .(13)  In this 
evaluation, improved survival was associated with a variety of disease response patterns such as subject s who initially appeared to have progressive disease but later achieved response and 
those who had prolonged stable disease.  
Though ipilimumab is  generally well tolerated, a unique set of side effects, termed immune -
related adverse events (irAEs) has been seen during its clinical development . The most severe 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 6 of 70 irAE is generally considered to be an inflammatory entero colitis which requires prompt 
treatment with steroids and, in some cases, anti -TNF-alpha therapy . Unfortunately , a 
randomized trial evaluating the role of prophylactic budesonide in decreasing the rate of 
inflammatory colitis showed no benefit to this approa ch.(14)  Other common severe side effects 
relate d to ipilimumab include hepatitis, dermatitis (including toxic epidermal necrolysis), 
neuropathy, and endocrinopathy . The following clinically significant immune -mediated adverse 
reactions were seen in less than 1% of ipilimumab -treated subjects in one stu dy: nephritis, 
pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia. (7)  
1.3 Nivolumab  
Nivolumab enhances antitumor immunity by blocking another negative regulator of immunity, programmed cell death -1 (PD -1) and has demonstrated high response rates in a number of 
malignancies and improved OS  in subject s with melanoma. (15-17)  Since both ipilimumab and 
nivolumab act upon distinct components of the immune system, several studies are now investigating the combination of both ipilimumab and nivolumab. Impressive early efficacy was seen with an acceptable safety profile in one Phase 1 study .(18)  Impressive efficacy has also 
been seen in phase 2 and 3 trials where the combination of nivolumab and ipilimumab was shown t o improve response rates and progression free survival compared to ipilimumab 
alone .(19, 20) 
1.4 Radiotherapy for Melanoma  
Radiotherapy (R T) is commonly used to palliate symptoms arising from sites of metastatic 
melan oma .(21)  In one study, 9 of 23 subject s who received RT achieved a complete response in 
the irradiated area, including 3  of 23  subject s who were rendered free of disease for at least 
56 months after RT. (22)  RT for melanoma has also been shown to improve symptoms and 
prevent impending complications from metastatic disease . One prospective study evaluated 
palliative endpoints for 90 subject s with renal cell carcinoma and melanoma who underwent  
palliative RT . Improvements in two -thirds of the painful bone or soft tissue lesions were noted 
by investigators .(23)  
The most effective dose and schedule of RT for subject s with metastatic melanoma, however, is 
not completely clear. In a study conducted by Overgaard et al., there was no difference in 
response rate betwe en subject s receiving 5  Gy per fraction for 8 fractions versus  9 Gy per 
fraction for 3 fractions, though subject  numbers were small. (24)  In anoth er study, Sause et al. 
reported the results of the Radiation Therapy Oncology Group trial 83 -05, which assigned 137 
subject s with melanoma to 8  Gy per fraction delivered once weekly for 4 fractions or 2.5 Gy per 
fraction delivered 5 days per week for 20 to tal fractions .(25)  The response rates for both 
treatment arms were not statistically significantly different . These results  differed slightly from a 
retrospective analysis of 84 subject s conducted at the Mayo Clini c, which indicated that  higher 
doses of RT were associated with improved palliation and improved survival. (26)  Import antly, 
dose per fraction and location of the irradiated lesions did not appear to correlate with the effectiveness of RT in this study . 
It is generally believed that high -dose palliative RT is feasible for subject s with metastatic 
melanoma,( 24) but no rigorous evaluation of dosing schemes has been tested in large, 
randomized studies . The dose and fractionation may have immunologic implications . Schaue et 
al. found that immunologic effects an d tumor control in a B16 murine melanoma model 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 7 of 70 depended  upon dose and schedule of RT .(27)  Tumor co ntrol was most effective and 
immunologic effects were most profound when RT was delivered via 7.5  Gy per fraction . In 
another study, when RT was delivered with anti -CTLA4 therapy, synergy was not seen when a 
single fraction of 20  Gy of RT was delivered .(28)  A third preclinical study showed that 
conventionally fractionated RT abrogated the immunologic effects of RT .(29)  Many radiation 
oncologists feel that a higher dose per fraction approach may be pr eferable, thoug h prospective 
clinical evaluation of dose and schedule of RT in subject s with metastatic melanoma is 
necessary.  
  
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 8 of 70 2 Study Rationale  
2.1 Preclinical Rationale for Combining Radiotherapy and Checkpoint 
Blockade  
To increase the numbers of subject s who benefit from ipilimumab  and nivolumab , clinical trials 
have started combining checkpoint antibodies  with other therapeutic modalities , such as 
chemotherapy, targeted therapy, and other immunotherapy. One additional , similarly promising 
approach involves combining checkpoint antibodies  with RT.  In a Phase 1/2 study in metastatic 
castration -resistant prostate cancer, ipilimumab in combination with RT demonstrated clinical 
antitumor activity and manageable AEs. (30)  Other clinical trials exploring RT and  checkpoint 
antibodies are ongoing.  
Conceptually, all of these additional therapeutic modalities, including localized RT, could result 
in increased tumor destruction, releasing tumor antigens that provide further stimulus to T cells 
disinhibited by checkp oint blockade  therapy to enhance durable antitumor immunity . It is also 
possible that RT may alter the tumor microenvironment and render the tumor cells more 
susceptible to immunologic -mediated disease regression.  
In preclinical models, RT has been shown to enhance antitumor immune responses through multiple mechanisms , including increased antigen present ation in tumor draining lymph nodes 
and enhanced effector cell migration to the irradiated tumor. (29, 31)  In one study, tumors that  
received RT had improved localization of inflammatory cells into the tumor microenvironment 
following adoptive cell transfer, which  was associated with upregulation of vascular cell 
adhesion molecules in the tumor microvasculature that  may have played a mechanistic role . RT 
has also been shown to increase MHC -I expression and increase the efficacy of adoptive cell 
transfer. (32) 
In addition to RT’s direct immunologic effects, preclinical evaluation has demonstrated synergy 
with other immunotherapeutic app roaches . Specifically, when RT was combined with the 
immunostimulatory cytokine, FMS -like tyrosine kinase 3 (Flt3), in a lung cancer model, only mice 
who received RT with Flt3 had improved survival .(33)  This survival was associated with the 
reduced development of distant pulmonary metastatic disease . A functional immune system 
appeared to be important as the effect was not seen in mice with defici ent T cells . Regression of 
tumors outside of the irradiated field was also seen when Flt3 was combined with RT in a murine breast cancer model but not in mice treated with either modality alone. (34) 
The immunologic effects of RT may be further enhanced by concomitant anti -CTLA -4 or anti -PD-
1/PD -L1 therapy . In mouse models , CTLA -4 blockade alone resulted in no significant tumor 
growth inhibition, but when localized RT was administered in combination with CTLA -4 
blockade, antitumor effects were seen outside of the irradiated field —a phenomenon known as 
the abscopal effe ct.(28, 35)  Though the precise mechanisms involved in the abscopal effect are 
not completely clear, T cells appear to play a cen tral role .(34)  This phenomenon has been 
replicated in multiple solid tumor murine models (Susan Knox, personal communication).  RT and 
PD-1/PD -L1 blockade have also demonstrated synergy in preclinical models. (36, 37)  The triple 
combination of CTLA -4, PD -1, and RT has also been explored in preclinical models and suggests 
even greater efficacy when all three modalities are combined .(38) 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 9 of 70 2.2 Clinical Rationale for C ombining Radiotherapy and Checkpoint 
Blockade  
To evaluate the potential synergy between RT  and immunomodulatory therapy, Formenti et al. 
conducted a proof of concept study for subject s with multiple solid tumors combining RT and 
granulocyte -macrophage colo ny stimulating factor (GM -CSF) . They reported that  4 of the 12 
evaluable subject s (30%) experienced an abscopal response, defined as a partial response of at 
least 1 lesion outside of the treatment field .(39)  Though subject  numbers were low, recent data 
have additionally shown an unusually high systemic response rate when RT was combined with 
IL-2 therapy .(40)  
Other case reports have suggested synergy between radiotherapy and immunotherapy .(41-44)  
Retrospective analysis of subject s treated with palliative R T during their induction course of 
ipilimumab at 3  mg/kg indicates th at combination treatment is not associated with a higher rate 
of irAEs . Only one subject  experienced a grade ≥  3 event (diarrhea) , which  resolved after 
infliximab therapy . This side effec t could have been related to ipilimumab alone .(45) 
Whether the dose or sch edule of RT in combination with immunotherapy is relevant remains 
unknown.  Relatively low doses of conventionally fractionated RT (e.g., 30 Gy in 10 fractions) 
have been shown to be effective palliative therapy for melanoma. (23)  Higher doses of 
hypofractionated RT (e.g., 24 Gy in 3 fractions) are also frequently used in melanoma because of 
perceived “radio -resistance” due to high levels of sublethal DNA damage repair in melanoma 
cell lines, although prospective randomized clinical studies have never confirmed this .(24)  
However, the dose and fractionation of RT may have immunologic con siderations relevant for its 
combination with immunotherapy.  Preclinical studies of CTLA -4 blockade combined with RT 
have demonstrated the greatest delay in tumor regrowth and highest rates of complete tumor 
response with a dose of 24 Gy in 3 fractions (v ersus 20 Gy in 1 fraction or 30 Gy in 5 
fractions). (28)  Another study analyzing the effect of single dose s of radiation from 5 -15 Gy 
found that radiation doses of 7.5 Gy yielded the greatest proportion of tumor -reactive T cells to 
regulatory T cells. (27)  Most  importantly, these findings are consistent with our anecdotal 
clinical observations of abscopal effects in patients undergoing RT (both patients were treated 
with approximately 27 Gy in 3 fractions) during ipilimumab immunotherapy.    
Additional study of t he relationship between RT dose and fractionation is warranted, particularly 
when considering the best strategy to combine with nivolumab and ipilimumab for patients with 
melanoma.   This information would be beneficial for subsequent studies involving comb inations 
of nivolumab and ipilimumab in a variety of diseases and therapeutic settings.  
This proposed study is therefore b ased upon the preclinical evidence suggesting synergy 
between RT and immunomodulatory therapy and early promising clinical experiences .  The 
current study is designed  to be the first prospective evaluation  of the combination of 
ipilimumab, nivolumab, and RT .  
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 10 of 70 3 Experimental  Plan  
3.1 Study Design  
This is an open -label, multicenter pilot  Phase 1 study of the checkpoint antibodies ipilimumab 
and nivolumab  in combination with RT  in 18 subjects with unresectable Stage IV melanoma. All 
subjects will receive  concurrent  ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3  weeks 
for 4 doses  (Weeks 1 through 10) , followed by nivolumab mono therapy ( 240 mg  every 2  weeks ) 
through Week 18, with optional extended treatment with nivolumab as described in Section 
3.1.12 . (Note: per Amendment 5, nivolumab monotherapy continuing after Week 18  may be 
given as 480  mg every 4 weeks , starting on Week 2 0, followed by Weeks 24, 28, etc. ).  
Radiotherapy  will be initiated after the first dose and before the second dose of 
immunothe rapy.  
There will be  2 cohorts in the study:  
Cohort A :  
Subject s in Cohort A will initially receive a conventional total RT palliative dose of 30 Gy 
delivered over 2 weeks in 10 fr actions of 3  Gy each . Once 9 subject s have been accrued to 
Cohort A and completed the concurrent  ipilimumab and nivolumab therapy, if ≤  7 subject s have 
Grade 3 or 4 drug-  or radiation -related AEs, as per Section 3.1.6 , the safety of Cohort  A will be 
deemed acceptable and additional subject s will be accrued to Cohort B.  
Note: Grade 3 or 4 amylase or lipase abnormalities that are not associated with  clinical 
symptoms will not be included in the Cohort A safety assessment described above.  
Cohort B:  
Subjects in Cohort B will receive the  high -dose hypofractionated RT  for which t reatment of a 
target lesion will comprise a total palliative dose of 27  Gy delivered over 2 weeks in 3  fractions 
of 9 Gy each.  
Radiographic imaging will be performed at W eek 12 of therapy. As  responses to these 
immunotherapeutic antibodies do not always occur at the first assess ment time  point and RT 
effects may not be apparent at the W eek 12 evaluation, repeat radiographic assessment will 
take place after  6 additional weeks at W eek 18. Subjects with symptomatic progression will be 
removed from the study.  
3.1.1  Study Phase  
Pilot  Phase 1  
3.1.2  Enrollment/Randomization  
Subject s will be initially enrolled in Cohort A, with subsequent enrollment into Cohort B  as 
outlined in  Section 3.1.7. Enrollment will be under ongoing review by an internal  data safety 
monitoring panel (see S ection  3.1.14, Safety Monitoring and Study Stopping Rules).  
3.1.3  Blinding/Unblinding  
This will be an open -label study.  
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 11 of 70 3.1.4  Subject Population  
Subjects with unresectable, stage IV metastatic melanoma are eligible for this study, as detailed  
further in Section 5. 
3.1.5  Number  of Sites /Subjects  
This study will be conducted at 3  sites  in the US , with 18 subjects estimated for enrollment.  
3.1.6  Sample Size and Statistical Considerations  
This study is intended to ge nerate descriptive safety data. Nine subject s are anticipated for each 
cohort to enable a variety of disease presentations and RT  targets.  
Prior experience  with nivolumab and ipilimumab administered in combination h as been 
associated with a treatment -relat ed grade 3/4 toxicity rate of 5 3%.(19)  A rat ing of Grade 3/4 
drug-  or radiation -related toxicity is considered to be acceptable in Cohort A if ≤ 7 of 9  subject s 
(78%) are affected  (see exception in Section 3.1 , i.e., asymptomatic amylase and lipase 
abnormalities are not included ). This number was selected to avoid premature  closure of 
exploration of this approach.  
As this is the first prospective study of RT  plus ipilimumab and nivolumab, no historical controls 
are available to anticipate the rate of toxicity  of this triple combination regimen . 
3.1.7  Treatment Arms  and Treatment Schema  
Table 1 presents the schedule of treatment administr ation . 
Table 1. Treatment Schema  
  Checkpoint Antibodies  (IV)  
Cohort  
N Week  Ipilimumaba  Nivolumabb Radiotherapy  
Cohort A  
n = 9 1 3 mg/kg  1 mg/kg  30 Gy delivered over 2 weeks 
in 10 fractions of 3  Gy each  2 ̶ ̶ 
4, 7,  10 3 mg/kg  1 mg/kg  ̶ 
12, 14, 16, 18  ̶ 240 mg  ̶ 
20+b -- 240 mg Q2W or  
480 mg  Q4W  -- 
Cohort B  
n = 9 1 3 mg/kg  1 mg/kg  27 Gy delivered over 2 weeks 
in 3 fractions of 9  Gy each  2 ̶ ̶ 
4, 7,  10 3 mg/kg  1 mg/kg  ̶ 
12, 14, 16, 18  ̶ 240 mg  ̶ 
20+b -- 240 mg Q2W or  
480 mg  Q4W  -- 
RT will be initiated after the first dose and before the second dose of immunotherapy.  
Abbreviations: Gy = Gray; kg = kilogram(s); mg = milligram(s); N = number; IV  = intravenously ; Q2W = every 2 weeks; 
Q4W = every 4 weeks  
a Administered once every 3 weeks for 4 doses.  (3-week cycles)  
b Administered once every 3 weeks for 4 doses (at 1 mg/kg)  and then  240 mg once every 2 weeks.  
Note: per Amendment 5, nivolumab monotherapy continuing after Week 18 may be given as 480 mg every 4 weeks, 
starting on Week 2 0, followed by Weeks 24, 28, etc.  
See Section 6.1 for order of infusion.  
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 12 of 70 3.1.8  Dos ing Adjustments , Delays , and Discontinuations  
Dosing adjustment, delays , and discontinuations of RT should be managed in accordance with 
standard of care. See Section 6.2  for administration details.  
Dosing reductions  in response to toxicities of ipilimumab  or nivolumab  are not permitted. 
Dosing delays and discontinuations of ipilimumab  and nivolumab  should be managed in 
accordance with  Section  8.3. The following documents  may also be referenced : 
• YERVOY® (Ipilimumab) Package Insert: http://packageinserts.bms.com/pi/pi_yervoy.pdf   
• YERVOY® (Ipilimumab) Immune -mediated Adverse Reaction Management Guide:  
https://www.hcp.yervoy.com/pa ges/rems.aspx  
• Opdivo® (Nivolumab) Package Insert: http://packageinserts.bms.com/pi/pi_opdivo.pdf   
• Management Algorithms for Adverse Events Associated with Immuno -oncology Agents 
(see Section 8.3.1).  
Note: As durable disease stabilization and/or objective tumor response may be observed  after 
early progression, it is recommend ed that, in the absence of toxicity requiring discontinuation in 
accordance with the package insert, all 4 doses of concurrent ipilimumab and nivolumab be 
administered over the initial 12  weeks , even in the setting of apparent clinical progression, 
provid ed the subject’s performance status remains stable.  
Even in the event of a dose delay, disease assessments should be performed according to 
standard of care on  the originally scheduled study days.  
Dose modifications for radiotherapy as a result of toxicity are  allowed per the Investigator’s 
assessment.  
3.1.9  Dose -limiting Toxicity  
The DLT and MTD will not be defined or determined.   A safety review will be conducted when 9 
subject s have been accrued to Cohort A and completed the concurrent  ipilimumab and 
nivolumab  therapy .  If ≤ 7 subject s have G rade 3 or 4 drug-  or radiation -related AEs, the safety 
of Cohort  A will be de emed acceptable and additional subject s will be accrued to Cohort B.  The 
Cohort A assessment period for this evaluation will include the first 2 cycles of treatment, up to 
and including the pre -dose safety assessments scheduled for Cycle 3  (see S ection  4.1.2 ). 
Note: Grade 3 or 4 amylase or lipase abnormalit ies that are not associated with clinical 
symptoms will not be included in the Cohort A safety assessment described above.  
3.1.10   Subject  Withdrawal  from Treatment or from Study  
A subject  will be withdrawn from study  treatment  for any of the following reasons : 
1. Pregnancy or intent to become pregnant.  
2. Clinical, symptomatic or radiographic p rogression warranting  alternative treatment . 
3. Significant protocol violation or noncompliance that, in the opinion of the I nvestigator 
or Spons or, warrants withdrawal.  
4. Initiation of alternative anticancer therapy including another investigational agent.  
5. Development of intercurrent, non -cancer related illnesses that prevent either 
continuati on of therapy or regular follow -up. 
6. Withdrawal of consent  for further treatment . 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 13 of 70 7. Best medical interest of the subject (at the discretion of the Investigator ) 
8. Discontinuation criteria per Section 8.3 . 
 
Subjects who are withdrawn from study treatment should undergo the plann ed On Study 
Follow -up through 100 days after the last study drug administration  (see the Study Flow chart in 
Section  3.2) and enter the Post S tudy Follow -up phase  (see Section  3.1.16 ). 
A subject will be withdrawn from the study  for the following reasons:  
 
1. Best medical interest of the subject (at the discretion of the Investigator ) 
2. Withdrawal of consent for all follow -up. 
3. Lost to follow -up 
4. Death  
3.1.11  Subject Evaluability  and Subject Replacement  
Subject s in Cohort A are fully evaluable for safety review of the concurrent  ipilimumab and 
nivolumab  therapy if: 
1) they receive at least 1  dose of ipilimumab, nivolumab, or RT and have a Grade 3 or 4  
related  AE 
2) In the absence of a Grade 3 or 4 related AE, they fulfill the criteria for the Per- protoco l 
population  for safety and tolerability  as defined in Section 4.1.2 . 
Subject s in Cohort A who are not fully evaluable for safety review will be replaced .   
Subject s are considered evaluable for the secondary efficacy  endpoint s if they fulfill the Per-
protocol and  Intent to treat populations described in Section 4.2.2, or if they discontinue from 
the study due to symptomatic pro gression, death, or toxicity at any point.  
Subject s who discontinue the study and do not meet evaluability criteria may be  replace d. 
3.1.12  Optional Study Treatment Extension  
Treatment extension with nivolumab monotherapy beyond 18 weeks is permitted and will be 
managed at the Investigator’s discretion in accordanc e with standard practice. Subject s who  
require additional treatment will continue to be followed for efficacy assessments and On Study 
Follow -up (see Section  3.1.16 and Section 3.2 ). Details of extended nivolumab  monotherapy 
administration should be captur ed on the Drug Administration electronic case report form 
(eCRF ). 
3.1.13  Interim  Analysis  
An interim analysis  of safety will be performed after 9 subjects in Cohort A have complet ed 
concurrent  ipilimumab and nivolumab therapy in order to determine whether to proceed with 
enrollment into Cohort B (see Section  3.1). 
3.1.14  Safety Monitoring and Study Stopping Rules  
In accordance with the Adminis trative, Legal and Ethical Requirements section of the protocol 
(see Section 7), Safety Monitoring will be performed by an internal data safety monitoring panel, 
consisting of the Principal Investigators (and co -investigators as needed), the S ponsor ’s medical 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 14 of 70 monitor, and drug safety personnel from Bristol -Myers Squibb , the provider of the study drugs.  
Additional investigators and staff, or additional Sponsor personnel and consultants, shall 
partic ipate in reviews as indicated. An Independent Data Monitoring Board wil l not be utilized 
for this open -label study.  
The study will be suspended or possibly stopped prematurely for any of the following reasons:  
1. A death  that is unexpected and at least probably related to 1  or more of the study drugs  
and/or RT . 
2. Severe a naphylactic reaction (i.e., with respiratory and cardiovascular failure)  to 1 or more 
of the study drugs . 
3. Any events that, in the judgment of the medical m onitor, are deemed serious enough to 
warrant immediate review by the data safety monitoring panel.  
4. Any other safety finding assessed as related to 1 or more study drugs that, in the opinion of 
the internal data safety monitoring panel, contraindicates further dosing of study subjects.  
5. Any interim findings that, in the opinion of the I nvestigators and the Sponsor, suggest that 
the study treatment has no clinical benefit for the subject s. 
General criteria for premature trial termination are outlined in the A dministrative  Section  7. 
3.1.15  Duration of Study  
Duration of Treatment:  1 year  (subject s benefitting from nivolumab treatment may 
receive continued treatment)  
Enrollment Period:  2 year s 
Length of Study:  3 years  
Length of Survival Follow -up 3 years  
3.1.16    On Study and Post -Study Follow -up 
All subject s, whether they complete the study as planned, discontinue  treatment , or 
prematurely withdraw from the study as per Section  3.1.10 , will be followed as per institutional 
guidelines in accordance with the usual standard of care principles.  
On Study Follow -up w ill be conducted for 100 days after the last study drug administration 
according to the flowchart in Section  3.2.  Refer to Section 7.1.5  for information on recording 
AEs during the On Study Follow -up. 
In addition  to the On Study Follow -up, there will be a Post Study Follow- up, during which c linical 
outcomes data (dates of pr ogression/relapse and survival) will be collected at least every 
12 (± 1) weeks  for 3 years after completion of 100-day On S tudy Follow -up.  For subject s who do 
not continue Post S tudy Follow -up at one of the study sites after the end of study, the Principal 
Investigators or the clinical team, under the supervision of the P rincipal Investigator, will obtain 
the data through review of outside records or communication with the subject  or his/her  
physician.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 15 of 70 3.2 Study Flowchart  
Study Section  Screen  
ing Treatment Final Assessment  
and Ongoing 
Treatment/  
Assessmentsd On Study 
Follow -upa,e Post -Study  
Follow -up 
(Section  3.1.16)  
Study Week   Week 1 
(Cycle 1)  Week 4 
(Cycle 2)  Week 7 
(Cycle 3 ) Week 10 
(Cycle 4)  Week
12 Week 
14 Week
16 Week
18 
2 weeks (± 3 days) 
after last study drug  30 (±4), 70 (±4) 
and 100 -107 days 
after last study 
drug  (AEs and 
pregnancy tests)  (Starts after 
completion of 100 -
day On Study 
Follow -up) 
Q12W  (± 7 d) for 
3 years  Study Day  -28 to 0 
(or as 
stated)  1 22 
(± 3) 43 
(± 3) 64 
(± 3) 78 
(± 3) 92 
(± 3) 106 
(± 3) 120 
(± 3) 
Drug Administration Cohort A  
Ipilimumabf IV  X X X X        
Nivolumabf IV   X X X X X X X X Xd   
Radiotherapyb,f (30 Gy over 10 fractions 
of 3 Gy)   X        
  
Drug Administration Cohort B  
Ipilimumabf IV  X X X X        
Nivolumabf IV   X X X X X X X X Xd   
Radiotherapyb,f (27 Gy over 3 fractions 
of 9 Gy)   X        
  
Tumor & Disease Assessments  
Disease Staging (date/stage at first 
diagnosis and study entry)  X            
Disease Assessment by RECIST 1.1 and 
irRECIST  X     X   X Xd 
(Week 24, then 
Q12W ± 7 days )   
Other Procedures & Examinations  
Eligibility Assessment and Informed 
Consent  X            
Demographics (including  DoB, sex, 
height , race , ethnicity)  X            
Medical History  X            
Physical Exam (including weight)  X X X X X X X X X Xd   
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 16 of 70 Study Section  Screen  
ing Treatment Final Assessment  
and Ongoing 
Treatment/  
Assessmentsd On Study 
Follow -upa,e Post -Study  
Follow -up 
(Section  3.1.16)  
Study Week   Week 1 
(Cycle 1)  Week 4 
(Cycle 2)  Week 7 
(Cycle 3 ) Week 10 
(Cycle 4)  Week
12 Week 
14 Week
16 Week
18 
2 weeks (± 3 days) 
after last study drug  30 (±4), 70 (±4) 
and 100 -107 days 
after last study 
drug  (AEs and 
pregnancy tests)  (Starts after 
completion of 100 -
day On Study 
Follow -up) 
Q12W  (± 7 d) for 
3 years  Study Day  -28 to 0 
(or as 
stated)  1 22 
(± 3) 43 
(± 3) 64 
(± 3) 78 
(± 3) 92 
(± 3) 106 
(± 3) 120 
(± 3) 
Electrocardiogram (baseline and as 
clinically indicated)  X            
Vital Signs ( temperature , HR, BP, RR)  X X X X X X X X X Xd   
ECOG  Performance Status  X X X X X X X X X Xd   
Concomitant Medication s/Procedure s X X X X X X X X X Xd   
Adverse Events Assessment  X X X X X X X X X Xd X  
Laboratory Measurements & Assays  
Serum P regnancy Teste  X         Xd,e Xe  
Urine Pregnancy Test (collected pre -
dose)e  X  X  X   X (Q6W)d,e   
Chemistry (Na, K, Cl, CO 2, BUN, c reat., 
gluc., Ca,  Mg, total prot ., alb., T bili., AST, 
ALT, ALP , LDH; blood drawn before 
dosingg (-14 to 
0) 
X X X X X X X X X Xd,g   
Free T 3, Free T 4, TSH;  blood drawn 
before dosingg (-14 to 
0) 
X X X X X X X X X Xd,g   
Amylase, lipase;  blood drawn before 
dosing  (-14 to 
0) 
X X X X X X X X X Xd   
Blood Hematology (CBC with differential 
and platelets ; blood drawn before 
dosing)  (-14 to 
0) 
X X X X X X X X X Xd   
Research Blood Draw (60 mL ; blood 
drawn before dosing)  X  X  X       
Tumor Biopsy ( optional)c X X X X X X X X    
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 17 of 70 Study Section  Screen  
ing Treatment Final Assessment  
and Ongoing 
Treatment/  
Assessmentsd On Study 
Follow -upa,e Post -Study  
Follow -up 
(Section  3.1.16)  
Study Week   Week 1 
(Cycle 1)  Week 4 
(Cycle 2)  Week 7 
(Cycle 3 ) Week 10 
(Cycle 4)  Week
12 Week 
14 Week
16 Week
18 
2 weeks (± 3 days) 
after last study drug  30 (±4), 70 (±4) 
and 100 -107 days 
after last study 
drug  (AEs and 
pregnancy tests)  (Starts after 
completion of 100 -
day On Study 
Follow -up) 
Q12W  (± 7 d) for 
3 years  Study Day  -28 to 0 
(or as 
stated)  1 22 
(± 3) 43 
(± 3) 64 
(± 3) 78 
(± 3) 92 
(± 3) 106 
(± 3) 120 
(± 3) 
Progression and Survival Follow -up            X 
Abbreviations: alb. = albumin; ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; T bili. = total bilirubin; BP = blood pressure; BUN = 
blood urea nitrogen; Ca = calcium; CBC = complete blood count; Cl = chloride; CO 2 = carbon di oxide; crea t. = creatinine; CT = computed tomography; d = day(s); DoB = date of birth; 
ECOG  = Eastern Cooperative Oncology Group; eCRF = electronic case report form;  gluc. = glucose; Gy = Gray;  HR = heart rate; irR ECIST  = immune- related RECIST ; IV = intravenous(ly); 
K = potassium; mL = milli liter(s); LDH = lactate dehydrogenase; Mg = magnesium; Na = sodium; prot. = protein; Q = every; RECIST = Response Evaluation Criteria for Solid Tumors; 
RR = respiratory rate; RT = radiotherapy; W = week(s) ; Q6W = every 6 weeks; Q12W = every 12 weeks 
Note:  Additional assessments may be evaluated at the Investigator’s discretion and per standard of care. Indicated assessments with in this chart define clinical data to be captured 
in the eCRF.  Standard of Care procedures may be used for eligibility assessments,  provided they meet the criteria specified in either the inclusion criteria or flowchart.  
a Subjects will be followed for 100 days after the last dose of study drug as a part of O n Study Follow -up; during this time, all AEs will be collected  at 30  (±4), 70 (±4) and 100- 107 days .   
b Radiotherapy will be delivered by standard or high dose palliative RT as per coho rt assignment.   
c Tumor biopsies are optional but are encouraged. Biopsies are prohibited from compromising the requirement for at least one me asurable lesion not undergoing RT.  
d Final Assessment  will be  2 we eks (± 3 days)  after last study drug , followed by On Study Follow -up and Post Study Follo w-up. A repeat disease assessment scan is not required at 
the final assessment visit if a scan was done within the previous 6 weeks before the final assessment visit. Subjects who do not continue treatment with nivolumab after Week 18  
do not need to have a repeat pregnancy test (if applicable)  at the final assessment if the subject had th is assessment at Week 18 .   
For those subjects who are continuing on nivolumab  after Week 18 at 240 mg every 2 weeks ±3 days , Study Visits will continue every 2 weeks ± 3 days during treatment , 
followed by the Final Assessment Visit , On Study Follow -up, and Post Study Follow -up after  the last nivolumab treatment.   
Per Amendment 5, nivolumab monotherapy continuing after Week 18 may be given as 480 mg every 4 weeks ± 3 days, starting on Week 20, followed by Weeks 24, 28, etc.  
For those subjects who are continuing on nivolumab  after Week 18 at 480 mg every 4 weeks  ±3 days , Study Visits will continue every 4 weeks ±  3 days during treatment, 
followed by the Final Assessment Visit, On Study Follow -up, and Post Study Follow -up after the last nivolumab treatment.  
Subjects continuing nivolumab monotherapy , subjects who complete study treatment as responder s, and subjects who have not progressed (either in irradiated or non- irradiated 
tumor burden)  will have an additional scan  (disease assessments by RECIST 1.1/ irRECIST ) at Week 24 and  subsequent scans Q12W (± 7 days ) until progression or start of 
alternate anti- cancer therapy . 
e For females of child -bearing potential (as defined in Section 5.2),  pregnancy tests required every 6 weeks and repeated at 30 (±4) days and 70 ( ±4) days after discontinuation of 
treatment.  Serum pregnancy test is  done at screening, final assessment, and during On Study Follow -up; urine pregnancy test is done at all other visits , including during continued 
nivolumab treatment  (Note: For females of child -bearing potential who are continuing on nivolumab after Week 1 8 at 480 mg every 4 weeks, urine pregnancy tests may be done 
every 8 weeks) . Urine pregnancy test is done and results confirmed pre treatment on Day 1 of study . 
f All subjects will receive concurrent nivolumab (1 mg/kg) followed by ipilimumab (3 mg/kg) on the same day every 3  weeks for 4 doses, then followed by nivolumab monotherapy 
(240 mg every 2 weeks ±3 days)  See footnote d for ongoing nivolumab monotherapy  after Week 18.   Radiotherapy will be initiated after the first dose and before the seco nd dose 
of immunotherapy.  
g Per Amendment 5:  After Week 18, LDH testing  and TSH (with reflexive free T3/T4) testing during ongoing nivolumab treatment will be done as clinically indicated ; other testing 
will continue per flowchart .  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 18 of 70 4 Study Objectives & Endpoints  
Primary 
Objective 
[Endpoints]  Safety and Tolerability  [According to the NCI CTCAE , Version 4.03]  
Secondary 
Objectives 
[Endpoints]  
 • ORR by RECIST 1.1 and irR ECIST [ORR at Weeks 12 and 18]  
• DCR by RECIST 1.1 and irR ECIST  [DCR  at Weeks 12 and 18]  
• Duration of response  
• PFS 
• OS 
Exploratory 
Objectives 
[Endpoints]  Antitumor Immunity  [Immunological Effects of Ipilimumab/Nivolumab /RT] 
CTCAE =  National Cancer Institute Common Terminology Criteria for Adverse Events; DCR = disease control rate ; 
irRECIST  = immune- related RECIST ; ORR = objective response rate; OS = overall survival; PFS = progression -free 
survival;  RECIST = Response Evaluation Criteria in Solid Tumors ; RT = radiotherapy  
4.1 Safety and Tolerability  
The safety and tolerability of ipilimumab and  nivolumab  in combination with RT  will be 
determined . Safety will be evaluated by the internal data safety monitoring panel on an 
ongoing basis, based on data review and regular conference calls with the investigators.  
4.1.1  Endpoints & Assessment Methods  
Clinical laboratory tests, vital sign m easurements, physical examinations, and subject interviews 
will be performed to detect new abnormalities and deteriorations of any pre -existing conditions. 
The investigator will evaluate any laboratory abnormalities for clinical significance, and clinically 
significant abnormalities will be recorded as AEs . All treatment- emergent, clinically significant 
abnormalities and deteriorations from the time of informed consent to the End of Study Visit 
should be recorded in the eCRFs  as AEs and graded according to the National Cancer Institute 
(NCI) Common Terminology Criteria for Adverse Events (C TCAE ), Version 4.03.  
4.1.2  Subject Evaluation & Statistics  
The Intent- To-Treat (ITT) Population  for safety and tolerability is defined as all subjects who 
receive at least one dose of study drug or RT.  The Per-Protocol (PP) P opulation for safety and 
tolerability is defined as all subjects  who received at least 75%  of the scheduled doses of study 
drugs and RT over the first 2 cycles, as well as , respective safety assessments  (up to and 
including the pre -dose assessments scheduled for Cycle 3)  without maj or protocol violation s 
over the entire Cohort A concurrent  ipilimumab and nivolumab  assessment period (as defined in 
Section  3.1.9) .   
For both cohorts, the overall analysis of safety and tolerability will be based on the ITT Population.  
Appropriate summaries of AEs, laboratory data, and vital sign data will be presented .  AEs will be 
listed individually per subject according to the NCI CTCAE , Version 4.03, and the number of 
subjects experiencing each AE will be summarized using descriptive statistics.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 19 of 70 4.2 Clinical Efficacy  
4.2.1  Endpoints & Assessment Methods  
Clinical efficacy will be  determined by objective response rate (ORR), disease control rate ( DCR), 
duration of response, p rogression -free survival (PFS), and overall survival (OS).  The primary 
method of assessment of tumor response will be the Response Evaluation Criteria for Solid 
Tumors ( RECIST ) 1.1, and the  secondary method of response evaluation will be irRECIST ( see 
Section  8.4) 
4.2.1.1  Tumor Response and Overall Response Rate  
4.2.1.1.1  Tumor Response o utside the Irradiated Fields  
ORR will be evaluated at Weeks 12 and 18 as a secondary endpoint of this study.  
Tumor imaging assessments (e.g. , CT, MRI, PET, etc.) of chest, abdomen, pelvis, and CNS for 
assessment of tumor size and distribu tion may be employed as deemed appropriate by 
investigators. Every attempt should be made to use whichever imaging technique(s) test(s) are 
used initially for repeat eva luations throughout the study. End of study tumor assessment will 
be 6 weeks from prior  assessment, at the Investigator’s discretion, and in accordance with the 
appropriate evaluation method.  
Radiographic imaging evaluations are considered standard of care for subject s treated with 
ipilimumab /nivolumab . Subject s treated off protocol with apparent progressive disease at 
Weeks 12 or 18 are encouraged to undergo a repeat radiographic assessment of disease 
approximately 4  to 6 weeks later to confirm progression.  
Study radiologists will be informed as to which lesio ns are intended to undergo RT. The lesions 
undergoing RT will not be included in the total tumor burden assessment. A separate calculation 
of response within the irradiated field will be determined as described in Section  4.2.1.1.2.  
4.2.1.1.2  Tumor Response within  Irradiated Fields  
Since the lesions that undergo RT are not included in the overall tumor burden for purposes of overall response assessments, response within the irradiated field will be separately 
determined.   
The determination of response within the irradiated tumor burden is an independent calculation from the determination of response overall for the tumor burden that does not receive RT.  
4.2.1.2  Disease Control Rate  
Disease Control Rate ( DCR ) will be evaluated at Weeks 12 and 18 as a secondary endpoint of this 
study. DCR is defined as the percentage of evaluable subjects with SD, PR, or CR . 
4.2.1.3  Duration of Response  
Duration of r esponse will be determined for each subject  with time origin at the first occurrence 
of response until the first occurrence of progression or date of death if the subject  dies due to 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 20 of 70 any causes before progression. Every effort will be made to follow subjec ts for progression after 
they discontinue the study.  
4.2.1.4  Progression -free Survival  
PFS will be defined as the number of days from the date of  the first dose of study drug to the 
date of earliest disease progression based on the appropriate response evaluation method , or to 
the date of death, if disease progression does not occur.  Subjects who do not progress and are 
still alive will be censored on the date of last follow -up or start of new treatment, whichever 
comes first . Every effort will be made t o follow subjects  for progression after they discontinue 
the study.  
4.2.1.5  Overall Survival  
OS will be measured for each subject  from the date of the first dose of study drug  until the 
recorded date of death or last follow -up. Subjects who are  still alive will be  censored on the date 
of last follow -up. Every effort will be made to follow subject s for OS  after they discontinue the 
study.  
4.2.2  Subject Evaluation & Statistics  
The Intent- To-Treat (ITT) Population for clinical efficacy is defined as all subjects who receive  at 
least one dose of study drug or  RT.   
The Per -Protocol (PP) Population for clinical efficacy is defined as all subjects who received at 
least 75% of the scheduled doses of the study drug and RT over the first 2 cycles, as well as, 
respective disease as sessments, without major protocol violations.   
The analysis will be based on both ITT and PP populations.  
Tumor Response will be summarized and analyzed descriptively for each cohort and analysis 
population .  
Tumor response rates will be assessed overall and for each cohort and tabulated with the 95% 
confidence intervals assuming binomial distribution.  
For time -to-event analyses, Kaplan -Meier methodology will be implemented to estimate the 
median duration of response, median PFS, and median OS at W eeks 12 and 18.  
4.3 Antitumor Immunity  
4.3.1  Endpoints & Assessment Methods  
Exploratory immunologic objectives will be assessed from peripheral blood and tumor biopsy sample s according to the schedule in Section 3.2 to ass ess the influence of ipilimumab and 
nivolumab plus RT on assays, which may include but  may  not be limited to the following:  
• Lymphocyte phenotype using markers such as ICOS, PD -1, and CD25;  
• Quantities of myeloid -derived suppressor cells (MDSCs), defined as CD14+HLA -DRlow cells;  
• Antibody and functional T cell responses to tumor associated antigens (i. e., NY-ESO-1) for 
relevant subject s; 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 21 of 70 • Serum cytokine levels such as TNF -alpha, IFN-gamma, IL -1beta, IL -2, IL-4, IL-5, IL-6, IL-8, 
IL-10, IL- 12, and TGF -beta;  
• Serum and plasma microparticle and exosome nanoFACS and proteomic profiles;  
• T cell repertoire diversity in peripheral blood and tumor.  
Immunologic characteristics will be summarized descriptively. Antibody, T cell phenotype, and 
functional T -cell responses will be assessed. Antibody responses will be measured using ELISA 
and a positive antibody response will be defined as extrapolated reciprocal titers >  100 post 
treatment. Intra cellular cytokine staining will be utilized to assess C D4+ and CD8+ T cell 
responses. Samples collected after treatment will be considered positive for response if they are 
higher than baseline values by at least 3 standard deviations. Therefore, for each subject , the 
standard deviation of the pre -treatment at two separate time  points (using 6 replicates each) 
will be computed, and a positive will be defined as greater than 3 times this value and greater 
than 0.1% after 10 -day in vitro stimulation.  
Addition al investigational methods may be used to characterize and measure components of 
the immune response based upon the latest available technology.  
4.4 Additional Exploration of Immune Response  
The methods used to analyze immune response to cancer antigens used in this study are well established. However, as cellular biology and immune regulation are very active fields of discovery, the opportunity exists to refine and extend the analysis of immune response. Therefore, although most of the blood dra wn for the analysis of the immune response is 
planned for the assays listed, a small part, if still available, may be used to explore other aspects of immunological response. This work may also involve assessing exosomes and markers associated with radiati on-induced immunologic cell death, such as expression of calreticulin and 
extracellular release of HMGB1. There may also be interest in establishing T -cell lines and clones 
in culture, evaluating tumor antigen -specific immune responses such as those agains t NY -ESO-1, 
assessing TCR repertoire diversity, proteomics/seromics analyses, and using samples in collaborations with other investigators and laboratories including those outside of the Ludwig 
Institute.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 22 of 70 5 Subject  Eligibility  
Note: Standard of Care procedures may be used for eligibility assessments provided they meet 
the criteria specified in either the inclusion criteria or flowchart . 
5.1 Inclusion Criteria  
Eligible subject s must fulfill  all of the following criteria:  
1.  Histologic diagnosis  of stage IV metastati c melanoma, with 1 melanoma lesion that can be 
safely irradiated  and,  in the opinion of the radiation oncologist , is of benefit to the subject  
to irradiate  (note: subjects with primary ocular and mucosal melanoma are permitted) . 
Lesions may include, but ar e not limited to:  
a. Symptomatic lymphadenopathy ; 
b. Bothersome cutaneous disease ; 
c. Hepatic metastases ; 
d. Pulmonary metastases.  
2.  Excluding the lesion intended to undergo radiation, subjects must have at least 1 
unresectable, non -bony lesion that is measurable radiographically (based on RECIST 1.1) . 
3.  Any number of prior therapies  (including none) . 
For subjects who have received prior systemic treatment with CTLA -4, PD -1, and/or PD-L1 
therapy, the last monoclonal antibody administration should be no less than 4 weeks prior 
to start of this protocol therapy and all prior side effects must have resolved to grade 1 or 
less by the time of the start of this protocol therapy.  
4.  Subject s must have : 
• Completed investigational therapy, other immunotherapy,  or prior RT at least 28 days 
before administration of the first dose of study drug(s)  
• Completed chemotherapy or targeted therapy  at least 14  days before administration 
of the first  dose of study drug(s)  
• Sufficiently recovered from prior surgery as determined by the treating I nvestigator.  
Clinically significant toxicity or pharmacodynamic effects experienced during any prior 
therapy must be resolved or stabilized before the first dos e of study drug(s) . 
5.  ECOG p erformance stat us of 0-1. 
6.  Life expectancy ≥ 4 months.  
7.  Screening l aboratory parameters : 
a. White blood cell ( WBC)  count ≥ 2000/µL ; 
b. Absolute neutrophil count ( ANC ) ≥ 1500/µL; 
c. Platelets ≥ 100,000 /µL; 
d. Hemoglobin ( Hgb)  ≥ 9 g/dL;  
e. Aspartate aminotransferase ( AST) and alanine aminotransferase ( ALT) ≤ 3 × upper 
limit of normal (ULN) ; 
f. Total b ilirubin ≤ 1.5 × ULN (< 3 mg/dL  for subjects with Gilbert’s disease) ; 
g. Serum c reatinine  ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥  40 mL/min (if using 
the Cockcroft -Gault formula below):  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 23 of 70 Female  CrCl = [(140 - age in years) x weight in kg x 0.85 ] / [72 x serum creatinine in mg/dL ] 
Male  CrCl = [(140 - age in years) x weight in kg x 1.00 ] / [72 x serum creatinine in mg/dL ] 
8.  Age ≥ 18 years.  
9.  Able and willing to give valid written informed consent.  
5.2 Exclusion Criteria  
Subject s may not  enter the study if they fulfill any of the following criteria:  
1.  Unresolved irAEs following prior biological therapy.   Subjects with asymptomatic 
endocrinopathy may enroll . 
2.  Active  autoimmune disease  or any condition requiring  systemic treatment with either 
corticosteroids ( >10 mg daily of prednisone equivalent s) or other immunosuppressive 
medications within 14 days of study drug administration. Inhaled or topical steroids and 
adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.  
3.  History of m otor neuropathy considered to be of autoimmune origin (e .g., Guillain -Barre 
Syndrome, Myasthenia Gravis).  
4.  Other active, concurrent malignancy  that requires ongoing systemic treatment or 
interfere s with  radiographic  assessment of melanoma response as determined by the 
investigator.  
5.  Active brain metastases or leptomeningeal metastases. Subjects with brain metastases 
are eligible if metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for 4 weeks or more after treatment is complete and within 28 days prior to the first dose of nivolumab administration. There must also be no requirement for immunosuppressive doses o f systemic corticosteroids (> 10 mg/day 
prednisone equivalents) for at least 2 weeks prior to study drug administration . 
6.  Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to 
Hepatitis B or C without evidence of active infection may be allowed.  
7.  History of severe allergic reactions to any unknown allergens or any components of the 
study drugs.  
8.  Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders).  
9.  Requirement of RT to treat brain metastases or receipt of  any non-study  systemic therapy 
for cancer or any other experimental /investigational treatment . 
10.  Mental impairment that may compromise the ability to give informed consent and 
comply with the requirements of the stu dy. 
11.  Lack of availability for immunological and clinical assessments or post -study follow -up 
contact to determine relapse and survival.  
12.  Women who are breastfeeding or who are pregnant as evidenced by a positive serum 
pregnancy test (minimum sensitivity 25 IU /L or equivalent units of HCG) performed within 
14 days of the first dose of study drug and by a urine pregnancy test (minimum sensitivity 
25 IU/L or equivalent units of HCG) within 24 hours of the first dose of study  drug(s) . 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 24 of 70 13.  Females of childbearing potential who are sexually active with a nonsterilized male 
partner must use 2 methods of effective contraception from screening, and must agree to 
continue using such precautions for 23 weeks  after the final dose of investigational 
product; cessation of birth control after this point should be discussed with a responsible 
physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control.  
[Females of childbearing potential are de fined as those who are not surgically sterile (i.e., 
bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmeno -
pausal (defined as 12 months with no menses without an alternative medical cause).] 
Nonsterilized males who are sex ually active with a female partner of childbearing 
potential must use 2 acceptable methods of effective contraception from Day 1 and for 
31 weeks  after receipt of the final dose of investigational product.  
Acceptable methods of effective contraception are described in the following table:  
Barrier Methods  Intrauterine Device Methods  Hormonal Methods  
Male condom plus spermicide, 
cap plus spermicide, or 
diaphragm plus spermicide.  Copper T, or Levonorgestrel -
releasing intrauterine system 
(e.g., Mirena®), also considered a 
hormonal method.  Implants, hormone shot or 
injection, combined pill, minipill, 
or Patch.  
 
14.  Any condition that, in the clinical judgment of the treating physician, is likely to interfere 
with the interpretability of the data or prevent the subject from complying with any 
aspect of the protocol or that may put the subject at unacceptable risk.  
  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 25 of 70 5.3 Restrictions on Concomitant Therapies  
5.3.1  Non -Permitted Concomitant Therapies  
Subject s may not  receive the following concomitant therapies during the study , except as 
allowed in Section 5.3.2:  
1.  Systemic treatment with high -dose glucocorticos teroids (> 10 mg daily prednisone 
equivalents) or other immunosuppressive treatments (e.g., methotrexate, 
chloroquine, azathioprine , adalimumab ), with a wash -out period  of 2 weeks prior to 
Day 1, unless such treatment is required to treat potential AEs . 
2.  Other non-study cancer therapy , with a wash -out period  of 4 weeks (2 weeks for 
chemotherapy, 6 weeks for nitrosoureas , and 12 weeks for  antibodies  other than 
CTLA -4, PD -1, and/or PD -L1 antibodies ) prior to Day  1. 
3.  Any other investigational agents.  
The wash -out period prior to Day 1 of the study for all non -permitted drugs should be at 
least 1 week, unless stated otherwise above.  
5.3.2  Permitted Concomitant Therapies  
Subject s may  receive the following concomitant therapies during the study:  
1.  At the discretion of the investigator, any drug or non -drug therapy necessary to treat 
any condition arising during the study, including high dose corticosteroids  to treat 
study -drug- related imm une-mediated adverse reactions.  Subjects should receive full 
supportive care, including transfusions of blood and blood products, and treatment 
with antibiotics, anti- emetics, anti -diarrheal, and analgesics, and other care as deemed 
appropriate, and in accordance with their institutiona l guidelines. Use of 
anticoagulants such as warfarin is permitted ; however, caution shou ld be exercised 
and additional international normalized ratio (INR) monitoring is recommended.  
Inhaled or topical steroids and adrenal replacement doses > 10 mg daily p rednisone 
equivalents are permitted in the absence of active autoimmune disease.  
2.  As there is potential for hepatic toxicity with nivolumab or nivolumab/ipilimumab 
combinations, drugs with a predisposition to hepatoxicity should be used with caution 
in subject s treated with nivolumab -containing regimen s. 
All prescription and nonprescription drugs must be recorded in the concomitant medications 
section of the  eCRF , listing generic (preferably) or brand name, indication, dose, route , and 
dates of administration. All non -drug therapies must be recorded in the respective sections 
of the eCRF  or as AEs . 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 26 of 70 6 Study Drug Preparation and Administration  
All study drugs are manufactured in accordance with Good Manufacturing Practices (GMP).  
6.1 Ipilimumab and Nivolumab  
The text within this section is provided for guidance ; the current nivolumab and ipilimumab 
Investigator Brochure s should be consulted for complete information regarding the storage, 
preparation , and administration of the study drugs.  
Ipilimumab and Nivolumab Product Descriptions  
Product 
Description and 
Dosage Form  Potency  Primary Packaging  
(Volume)/Label 
Type  Secondary 
Packaging  
(Qty)/Label Type  Appearance  Storage 
Conditions  
(per label)  
Nivolumab 
(BMS -936558-
01) Solution for 
Injectiona 100 mg 
(10 mg/mL)  10 mL  / vial 5-10 vials per 
carton/ Open- label  Clear to opalescent 
colorless to pale 
yellow liquid. May 
contain particles  2 to 8 °C; 
Protect fro m 
light and 
freezing  
Ipilimumab 
Solution for 
Injection  200 mg 
(5 mg/mL)  40 mL  / vial 4 vials per 
carton/Open- label  Clear, colorless to 
pale yellow liquid. 
May contain 
particles  2 to 8°C;  
Protect from 
light and 
freezing.  
aNivolumab may be labeled as BMS -936558- 01 Solution for Injection . 
If stored in a glass front refrigerator, vials should be stored in the carton. Recommended safety 
measures for preparation and handling of nivolumab and ipilimumab include laboratory coats and gloves . 
When study drugs (ipilimumab or nivolumab) are to be administered on the same day, separate infusion bags and filters must be used for each infusion. It is recommended that nivolumab be administered first , as a n IV infusion  over approximately 60 minutes  (or 30 minutes ; see note) , 
followed by ipilimumab  administered as an IV infusion over approximately 90 minutes  (or 30 
minutes)  that start s approximately 30 minutes after completion of the nivolumab infusion.  
Note: an infusion time of 30 minutes may also be  used for each of the drug infusion s (i.e., 30-
minute infusion for nivolumab→30 -minute interval→30 -minute infusion for ipilimumab ) as 
described by Martin -Algarra, et al. (46)   
Dosing calculations should be based on body weight. If the subject’s weight on the day of dosing 
differs by > 10% from the weight used to calculate the dose, the dose must be recalculated. All doses should be rounded up or to the near est milligram or as per  local  institutional standard.  
Due to parameters surrounding the use time of nivolumab and ipilimumab, the time of 
preparation should be noted in the Pharmacy Source documents (accountability logs) or in study 
files as required for investigator -sponsored research (FDA and GCP).  
6.1.1  Nivolumab Storage Conditions & Handling  
• Store at 2 °C to 8°C (36°F to 46°F) ; protect from light, freezing, and shaking.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 27 of 70 • Please report an y temperature excursions encountered during storage to BMS for 
assessment via the Tempera ture Excursion Response Form.  
• As with all injectable drugs, care should be taken when handling and preparing nivolumab. 
Whenever possible, nivolumab should be prepared in a laminar flow hood or safety cabinet 
using standard precau tions for the safe handling of IV  agents applying aseptic technique.  
• Partially used vials should be disposed of at the site following procedures for th e disposal of 
anticancer drugs.  
• After final drug reconciliation, unused nivolumab vials should be dispose d at the site 
following procedures for the disposal of anticancer drugs.  
For details regarding nivolumab preparation, storage, and administration please refer to the 
pharmacy reference sheets/Investigator Brochure.  
6.1.2  Nivolumab Preparation and Administration  
For details regarding nivolumab preparation, storage, and administration please refer to the pharmacy reference sheets/Investigator Brochure.  
1. Visually inspect the drug product solution for particulate matter and discolor ation prior to 
administration. Disca rd if solution is cloudy, if there is pronounced discoloration (solution 
may have a pale -yellow color), or if there is foreign particulate matter other than a few 
translucent -to-white, amorphous particles.   Note: Mix by gently  inverting several times. Do 
not shake.  
2. Aseptically withdraw the required volume of nivolumab solution into a syringe, and dispense 
into an IV bag. If multiple vials are needed for a subject, it is important to use a separate sterile syringe and needle for each vial to prevent problems such as dulling of needle tip, 
stopper coring, repeated friction of plunger against syringe barrel wall. Do not  enter into 
each vial more than once. Do not  administer study drug as an IV push or bolus injection . 
3. Add the approp riate volume of 0.9% Sodium Chloride Injection solution or 5% Dextrose 
Injection solution. It is acceptable to add nivolumab solution from the vials into an 
appropriate pre -filled bag of diluent . 
4. Note:  Nivolumab infusion concentration must be at or above  the minimum allowa ble 
concentration of 0.35 mg/mL . 
5. Note:  It is not recommended that so -called “channel” or tube systems are used to transport 
prepared infusions of nivolumab.  
6. Attach the IV bag containing the nivolumab solution to the infusion set and filter . 
7. At the end of the infusion period, flush the line with a sufficient quantity of approved diluents.  
Additional information: 
1. The administration of nivolumab infusion must be completed within 24 hours of 
preparation . If not used immediately , the infusion so lution may be stored under 
refrigeration conditions (2°C to 8°C, 36°F to 46°F) for up to 24 hours, and a maximum of 8 
hours of the total 24 hours can be at room temperature (20°C to 25 °C, 68°F to 77°F) and 
room light . The maximum of 8 hours under room temperature and room light conditions 
includes the product administration period.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 28 of 70 2. Nivolumab  injection is to be administered as an IV infusion through a 0.2 -micr on to 1.2 -
micron pore size, low -protein binding (polyethersulfone membrane) in -line filter at th e 
protocol -specified doses and infusion times. It is not to be administered as an IV push or 
bolus injection. When the dose is based on subject weight (ie, mg/kg), nivolumab injection 
can be infused undiluted (10 mg/mL) or diluted with 0.9% sodium chloride  injection, USP or 
5% dextrose injection, USP to protein concentrations as low as 0.35 mg/mL. When the dose 
is fixed (eg, 240 mg or 480 mg flat dose), nivolumab injection can be infused undiluted or diluted so as not to exceed a total infusion volume of 12 0 mL.  
6.1.3  Ipilimumab Storage Conditions & Handling  
For details regarding preparation, storage, and administration please refer to the pharmacy reference sheets/Investigator Brochure.  
Ipilimumab injection may be stored undiluted (200 mg/vial [5 mg/mL]) or follo wing dilution to 
concentrations between 1 mg/mL and 4 mg/mL in 0.9% Sodium Chloride Injection (USP), or 5% Dextrose Injection (USP) in PVC, non -PVC/ or glass containers for up to 24 hours under  
refrigerat ed conditions  (2°C to 8°C)  or at room temperature .  For longer storage, ipilimumab 
should be kept refrigerated (2°C to 8°C) with protection from light.  Ipilimumab injection must 
not be frozen.  
Partially used vials or empty vials of ipilimumab injection should be discarded at the site 
according to appropriate drug disposal procedures.  
6.1.4  Ipilimumab Preparation and Administration  
As this is provided  for guidance only, please see I nvestigator brochure for additional information 
regarding preparation and administration.  
1. As ipilimumab is stored long -term a t refrigerated temperatures (2°C to 8°C)  and protected 
from light, allow the appropriate number of vials of ipilimumab to stand at room temperature for approximately 5  minutes.  
2. Ensure that the ipilimu mab solution is clear, colorless  and essentially free fr om particulate 
matter on visual inspection. If multiple vials are needed for a subject, it is important to use a separate sterile syringe and needle for each vial to prevent problems such as dulling of needle tip, stopper coring, repeated friction of plunger against syringe barrel wall, etc.  
3. Aseptically transfer the required volume of ipilimumab solution into a syringe. [ Note: A 
sufficient excess of ipilimumab is incorporated into each vial to account for withdrawal losses. ] 
4. Do not draw into each vial more than once. Discard partially used vials or empty vials.  
5. Ipilimumab solution should be added to an appropriate size infusion container to accommodate the calculated final volume.  Total dose should be calculated using the most 
recent subject weight; if weigh t on dosing day differs by 10% from prior weight used to 
calculate dosing, the dose should be recalculated and study drug adjusted accordingly.  
6. Mix by GENTLY inverting several times. DO NOT shake.   
7. Ipilimumab injection may be diluted in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP.  
8. Visually inspect the final solution. If the initial diluted solution or final solution for infusion is not clear or contents appear to contain precipitate, the solution should be discarded.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 29 of 70 9. Immediately after  the infusion is complete, flush with an adequate amount of 0.9% Sodium 
Chloride injection (USP) or 5% Dextrose injection (USP) to completely flush the residual fluid 
(dead space) in your administration set (approximately 30  to 50 mL); this will ensure that all 
active drug is delivered to the study participant . 
10. Safely discard any unused portion of the infusion solution. Do not store for reuse.  
Ipilimumab should be administered under the supervision of a physician experienced in the use 
of IV agent s. Ipilimumab is administered as an IV infusion only . 
It is possible that sites may have more than one ipilimumab clinical study ongoing at the same time. It is imperative that only product designated for this protocol be used for this study.  
6.2 Radiotherapy  
RT will be initiated after the first and before the second dose of ipilimumab /nivolumab.  
Target volumes for RT will be defined in accordance with International Commission on Radiation 
Units and Measurements (ICRU) Report #50: Prescribing, Recording and Rep orting Photon Beam 
Therapy, and ICRU Report #71:  Prescribing, Recording and Reporting Electron Beam Therapy.  
The target lesion for RT  will be defined as the gross tumor volume (GTV). The clinical target 
volume (CTV ) will be the same as the GTV. The plannin g target volume (PTV) will be a minimum 
volumetric expansion of the GTV by 2 mm (5 mm recommended), but ultimately will be left to the discretion of the attending radiation oncologist.  
CT simulation will be performed for planning purposes. Details of the C T simulation (4D CT, 
gating, use of contrast, immobilization) will be left to discretion of the attending radiation oncologist.  
RT will be planned in 3 -D and may be delivered using conventional, IMRT or rapid arc 
methodology. 6-18 MV photons and/or electro n beam RT  will be used as determined by t he 
specific clinical situation.  95% of the PTV should receive th e prescription radiation dose. Normal 
tissue constraints (see  Section  8.5) will not be exceeded during the planning process.  
When photon therapy is used, portal imaging, cone beam CT, or 2D kV on board imaging for QC 
will occur for each treatment.  When electron therapy is used, light field verification of the targ et 
will occur at the start of treatment.  
6.3 Drug Overdose Management  
Any overdoses with the study drugs should be managed according to the appropriate package 
inserts. All overdoses (excess of 10% or more) must be reported, with or without associated 
AEs/ serious adverse events ( SAEs ), according to Section  7.1.5  and Section 7.1.6.  
  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 30 of 70 7 Administrative, Legal & Ethical Requirements  
7.1 Documentation and Reporting of Adverse Events  
7.1.1  General AE/SAE Definitions per ICH Guidelines  
An Adverse Event (AE)  is any untoward medical occurrence in a patient  or clinical investigation 
subject administered a pharmaceutical product and that does not necessarily have a causal 
relationship with the treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.  
N.B.:  The definition above, prov ided for in the GCP -ICH Guideline E6, is being extended for the 
purpose of LICR studies to include any events, intercurrent diseases and accidents observed 
while the subject  is on study, i.e., during the actual treatment period, as well as during drug -
free, pre - and post -treatment periods .,  
A Serious Adverse Event (SAE) is any untoward medical occurrence that:  
1. Results in death,  
2. Is life -threateningA, 
3. Requires inpatient hospitalization or prolongation of existing hospitalization,  
4. Results in persistent or sig nificant disability or incapacity,  
5. Is a congenital anomaly / birth defect or  
6. Is another medically important conditionB. 
A The term “life -threatening” in the definition of “serious” refers to an event in which the 
patient/ subject  is at risk of death at the time of the event; it does not refer to an event, 
which hypothetically might have caused death if it were more severe.  
B Medically important conditions that may not result in death, be immediately life -
threatening or require hospitalization may be considered as SAE when, based upon appropriate medical judgment, they may jeopardize the patient/ subject  or may require 
intervention to prevent one of the outcomes l isted in the definition above. Examples of such 
events are intensive treatment in an emergency room  or at home for allergic 
bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; or development of drug dependency or drug abuse.  
N.B.:  The term “severe” is often used to describe the intensity (severity) of an event (such as: 
mild, mod erate, or severe, e.g., pain). The event itself may be of relatively minor medical 
significance (such as severe headache). This is not the same as “serious”, which is based on 
subject /event outcome or action criteria usually associated with events  that pose a threat to 
subject ’s life or vital functions.  Seriousness (not severity) serves as a guide for defining 
regulatory reporting obligations.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 31 of 70 7.1.2  Additional SAE Definitions for this Study  
For the purpose of this study, the following events are considered medically important 
conditions and must be treated as SAEs:  
1. Pregnancy . 
2. Overdose  (as defined in Se ction 6.3). 
3. Potential drug-induced liver injury (DILI) . 
Wherever possible, timely confirmation of initial liver- related laboratory abnormalities 
should occur prior to the report ing of a potential DILI event. All occurrences of potential 
DILIs, meeting the defined criteria, must be reported as SAEs . Potential DILI is defined as:  
• ALT or AST elevation > 3 times upper limit of normal (ULN); AND  
• Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated serum alkaline phosphatase) ; AND  
• No other immediately apparent possible causes of AST/ALT elevation and hyperbilirubinemia, including, but not limited to, viral hepatitis, pre -existing chronic or 
acute liver disease, or the administration  of other drug(s) known to be hepatotoxic.  
4. Suspected transmission of an infectious agent (e .g., pathogenic or nonpathogenic) via the 
study drug.  
7.1.3  Severity of an Adverse Event  
The severity of all serious and non -serious AEs should be assessed according to th e NCI CTCAE 
Scale ( Version 4.03).  
7.1.4  Relationship of Adverse Events to Study Drug  
The relationship of all serious and non -serious AEs to the investigational agent(s) will be 
determined by the Investigator on the basis of their clinical judgment, using one of the following 
terms (in accordance with NCI Guideline “Expedited Adverse Event Reporting Requirements for NCI Investigational Agents”, NCI Cancer Therapy Evaluation Program, January 2001):  
Definitely related  (The AE is clearly related to the investigati onal agent)  
Probably related  (The AE is likely related  to the investigational agent)  
Possibly related  (The AE may be related to the investigational agent)  
Unlikely related  (The AE is doubtfully related to the investigational agent)  
Unrelated  (The AE is cle arly not related  to the investigational agent)  
N.B.:  When making the assessment on causality, it should be taken into consideration that 
immune -therapeutic agents have the potential to cause very late and/or permanent effects on 
the immune system, i.e., a causal relationship could exist despite a lack of apparent temporal 
relationship. Information provided in the IB and/or in Section  1 (Background) of this protocol 
may support these evaluations.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 32 of 70 7.1.5  General Reporting Requirements  
Documentation of serious and non -serious AEs includes: dates of onset and resolution, severity, 
seriousness, study drug intervention, treatment and outcome, as well as the causal relati onship 
between the event and the study drug in accordance with Section 7.1.4.  
All serious and non -serious AEs occurring between the date of signing the informed con sent and 
the off -study date  must be documented in the source records and on the respective section of 
the CRF, regardless of the assumption of a causal relationship . 
During the On Study Follow -up period, all AEs (not only those deemed to be treatment- related)  
will continue to be collected  for 100 days after the last dose of study drug  administration . 
7.1.6  Expedited Serious Adverse Event (SAE) Reporting Requirements  
In addition to the General Reporting Requirements specified in Section 7.1.5 , all SAE s, 
irrespective of suspected causation, must be reported by the I nvestigator to the Sponsor 
within 24 hours  of discovery, using the “Initial Serious Adverse Event Report Form”, provided 
by the Sponsor, or, if Medidata RAVE data capture is utilized, using the respective eCRFs. This 
includes any deaths that occur after the off -study date, but within 100  days of last study drug 
administration.  
Events meeting the criteria for an SAE as per Sections 7.1.1 and 7.1.2  must be reported to the 
Sponsor’s Drug Safety Contact  (primarily) or, alternatively, the Primary Sponsor Contact , via 
email or phone call within 24 hours o f becoming aware of the event. The event must also be 
recorded in the Adverse Event Log electronic CRF and indicated as an SAE  within 24 hours.  
Studies utilizing the Medidata “Safety Gateway”, built into the eCRF, and respective SAE 
reporting procedures, do not requ ire reporting by fax or email. Questions related to “Safety 
Gateway” procedures should be directed to the Drug Safety Contact or Primary Sponsor Contact  
(see table below) . 
In urgent cases, pre -notification via phone or informal e -mail should be considered.  
Drug Safety Contact:  
Gary O’Donnell, MS  
Senior Manager, Drug Safety  
Clinical Trials Management  
Ludwig Institute for Cancer Research  
666 3rd Ave 28th Floor  
New York, New Yor k 10017 
Tel: +1 212 450 1551  
Fax: +1 212 450 1535  
godonnell@licr.org  Primary Sponsor Contact:  
Mary Macri 
Director  
Clinical Trials Management  
Ludwig Institute for Cancer Research  
666 3rd Ave 28th Floor  
New York, New  York 10017 
Tel: +212 450 1546  
Fax: +212 450 1535  
mmac ri@licr.org  
 
SAEs must also be reported by the Principal Investigator to the respective Institutional Review 
Board after being assigned an  SAE tracking number by the Sponsor. Institutional Review Boards 
may have specific rules on which AE s need to be reported expeditiously, as well as, the time 
frames for such reporting.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 33 of 70 SAE Reports will be evaluated by the Sponsor’s Med ical Monitor. Regulatory au thorities and 
other investigators, as well as institutional and corporate partners, will be informed by the 
Sponsor as required by ICH guidelines, laws and regulations in the countries where the investigational agent is being ad ministered. In particular, S AEs that are unexpected and for 
which a causal relationship with the study drug (s) cannot be ruled out, will be reported by the 
Sponsor within 15 calendar days; if they are life -threatening or fatal, they will be reported within 
7 Calendar days.  
7.1.7  Serious Ad verse Event (SAE) Follow -up Requirements  
Subject s experiencing SAEs should be followed closely until the condition resolves or stabilizes, 
and every effort should be made to  clarify the underlying cause. Follow -up information related 
to SAEs must be submit ted to the Sponsor as soon as relevant data are available, using the “SAE 
Follow -up Report form”, provided by the Sponsor.  
7.2 Administrative Sponsor Requirements  
7.2.1  Study Master Files  
The Investigator must retain a Sponsor -specified comprehensive and centralized filing system 
(“Study Master File”) of all trial- related documentation that is suitable for inspection by the 
Sponsor and regulatory  authorities. Upon completion of the trial, the Investigator is required to 
submit a summary report to the Spons or. 
The Investigator must arrange for the retention of the Study Master File for a period of t ime 
determined by the Sponsor. No part of the Study Master File shall be destroyed or relocated without prior written agreement between the Sponsor and the Investigator.  
7.2.2  Case Report Form Data Collection  
Electronic CRFs will be completed in accordance with respective guidance and after training 
provided by the Sponsor. The use of eCRFs encompasses electronic data entry, query management and sign -off. Systems u sed for electronic data capture will be compliant with FDA 
regulations 21 CFR Part 11 and within the constraints of the applicable local regulatory agency 
guidelines (whichever provides the greatest protection to the integrity of the data).  
All subjects wh o sign an informed consent form , regardless of study procedures performed , will 
be assigned a screening number and have their data entered into the eCRF.  
The Investigator will sign and dat e the completed eCRF sections. This signature will indicate a 
thorou gh inspection of the data in the CRF and will certify its content.  
7.2.3  Language  
The p rotocol is written in English. All correspondence between the study site and the Sponsor 
should be maintained in English.  eCRFs  must be completed in English. All written material to be 
used by subjects and para -clinical staff must use vocabulary that is clearly understood, and be in 
the language appropriate for the trial site.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 34 of 70 7.2.4  Monitoring  
The Sponsor will oversee the conduct of the study and perform clinical monitoring visits fo r site 
qualification , site initiation, routine monitoring and site close -out. Clinical Monitors and/or 
other sponsor staff will meet with the investigator staff and require direct ac cess to source 
data/documents. Such access may also be required for Instit utional Review Board review, and  
regulatory inspection/audits. Direct access is defined as permission to examine, analyze, verify, 
and reproduce any records and reports that are important to the evaluation of the study.  All 
reasonable precautions within th e constraints of the applicable regulatory requirement(s) to 
maintain the confidentiality of subjects’ identities and sponsor’s proprietary information will be 
exercised.  
It is the Clinical Monitor’s responsibility to inspect the eCRF  at regular intervals throughout the 
trial to verify adherence to the protocol, the completeness, accuracy and consistency of the data, and adherence to Good  Clinical Practice guidelines. The Clinical M onitor should have 
access to subject charts, laboratory reports and other su bject records needed to verify the 
entries on the eCRF  (“source data verification”).  
7.2.5  Protocol Amendments  
Protocol amendments may be implemented only after approval by the Investigator, Sponsor, Institutional Review Board and, if required, the regulatory au thorities. Amendments that are 
intended to eliminate an apparent immediate hazard to subjects may be implem ented prior to 
such approvals. However, in this case, approval must be obtained as soon as possible after implementation. Implementation of administrative amendments that do not affect the safety of the subjects do usually not require prior Institutional Review Board approval, just notification.  
When immediate deviation from the protocol is required to eliminate an immediate hazard(s) to subjects, the Investigator will contact the sponsor if circumstances permit, to discuss the planned course of action. Any departures from the protocol must be fully documented in the source documentation.  
7.2.6  Premature Subject Withdrawal  
A subject may withdraw  from the study at any time for any reason without prejudice to his/her 
future medical care by the p hysician or at the study site. Likewise, the Investigator and/or 
Sponsor have the right to wit hdraw subjects from the study. Specific subject withdrawal rea sons 
are listed in Section 3.1.10. Should a subject (or a subject’s legally authorized representative) 
decide to withdraw, all efforts will be made  to complete the required study procedures and 
report the treatment observations as thoroughly as possible.  
A complete final evaluation should be made at the time of the subject’s withdrawal, the appropriate  form in the eCRF  should be completed with an exp lanation of why the subject is 
withdrawing, and an attempt should be made to perform a follow -up evaluation.  
7.2.7  Early Trial Termination  
“End of study” is defined as the last visit of the last subject.  Sponsor and Investigator have the 
right  to terminate the s tudy early. Specific study stopping rules are listed in Section 3.1.14. In 
such case, one party must notify the other in advance in writing about the intent of and th e 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 35 of 70 reasons for the termination. The investigator must also notify the appropriate Institutional 
Review Board accordingly . 
7.2.8  Study Drug Shipments & Accountability  
Study  drug shipments will be addressed to the Principal Investigator’s authorized designee, 
preferably the site’s pharmacy. The recipient will verify the amount and condition of the drug 
and will return a signed Acknowledgment of Receipt to the shipper.  
Initial  Orders:  
• Following submission and approval of the required regulatory documents, a supply of nivolumab and ipilimumab may be ordered from by completing a Drug Request Form 
provided by BMS for this specific trial.  
• The initial order should be limited to the amount needed for 2 doses. Allow 5 business days 
for shipment of drug from BMS receipt of the Drug Request Form. Drug is protocol specific, 
but not subject  specific. All drug products will be shipped by courier in  a temperature -
controlled container. It is possible that sites may have more than one nivolumab clinical study ongoing at the same time. It is imperative that only drug product designated for this protocol number be used for this study.  
• Pharmacy supplies n ot provided by BMS: Empty IV bags/containers, approved diluents, 
in-line filters , and infusion tubing.  
Re-Supply : 
• Drug re -supply request form should be submitted electronically at least 7 business days 
befo re the expected delivery date. Deliveries will be made Tuesday through Friday.  
• When assessing need for resupply, institutions should keep in mind the number of vials used per treatment dose, and that shipments may take 14 business days from receipt of requ est. 
Drug is not subject -specific. Be sure to check with your pharmacy regarding existing 
investigational stock to assure optimal use of drug on hand.  
Drug Excursions : 
• Drug excursions should be reported immediately to BMS on the form provided with the 
stud y-specific drug order form . 
A drug dispensing log (inventory) will be kept by the study site, containing at least the following:  
• the subject’s identification (subject number and code)  
• date and quantity of drug dispensed  
• date and quantity of drug retu rned to the investigator/pharmacy (if applicable)  
• date and quantity of accidental loss of drug (if any)  
These inventories must be made available for in spection by the Clinical M onitor. The 
Investigator is responsible for the accounting of all u sed and u nused trial supplies. At the end of 
the study, the Clinical Monitor will also collect the original study drug dispensing records.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 36 of 70 At the end of the study or as directed by the Sponsor, all used and unused supplies, including 
partially used or empty contain ers, will be disposed of or transferred as instructed by the 
Sponsor, and in accordance with local written procedures, if applicable.  Any disposal or transfer 
of investigational agent shall be noted on the investigational drug disposition log and  signed -off 
by a second person.  At the end of the study, the Clinical M onitor will collect the original drug 
disposition logs.  
7.3 Regulatory, Lega l, & Ethical Requirements  
7.3.1  Good Clinical Practice (GCP), Laws and Regulations  
The investigator must ensure that he/she and all authorized personnel for the study are familiar 
with the principles of Good Clinical Practice (GCP) and that the study is conducte d in full 
conformity with the current revision of the Declaration of Helsinki, ICH Guidelines and 
applicable local laws and regulations, with the understanding that local laws and regulations take precedence over respective sections in the Declaration of H elsinki and/or the ICH 
Guidelines.  
7.3.2  Informed Consent  
The investigator must obtain witnessed (if applicable) written informed consent from the subject or the subject’s legally authorized representative after adequate explanation of the aims, methods, anticip ated benefits, and potential hazards of the study and before any study -
spec ific procedures are performed. The subject should be given a copy of the informed consent 
documentation.  The original signed and dated informed consent form must be retained in the 
study records at the study site, and is subject to inspection by representatives of the Sponsor, or representatives from regulatory agencies.  
7.3.3  Institutional Review Board 
The investigator must obtain written approval from the appropriate Institutional Review Board for the protocol and informed consent, and all amendments thereof, prior to recruitment of subjects and prior to shipment of investigational agents.  
The investigator must report SAEs to the appropriate Institutional Review Board in accordance 
with the Institutional Review Board’s rules and guidelines (see also Section 7.1 ). 
The investigator must assure that continuing review  (at least once per year) of the study is 
performed by the Institutional Review Board through out the duration of the study. If so 
required by the Institutional Review Board, the investigator must provide study reports on an annual basis and upon completion  of the study.  
All correspondence with, and reports to, the Institutional Review Board must be maintained in 
the study files at the study site and copies must be sent to the Sponsor.  
7.3.4  Subject Confidentiality  
The investigator must ensure that the su bject’s p rivacy is maintained. A subject should only be 
identified by their initials, date of birth and subject number on the eCRF  or other documents 
submitted to the Spons or. Documents that are not submitted to the Sponsor (e.g., signed 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 37 of 70 informed consent form) shou ld be kept in a strictly confidential section of the study file by the 
Investigator.  
The investigator shall permit the Sponsor and authorized representatives of regulatory agencies 
to review the portion of the subject’s medical record that is directly rela ted to the study. As part 
of the informed consent process, the subject must have given written consent that his/her 
records will be reviewed in this manner.  
  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 38 of 70 8 Appendices  
8.1 Protocol Version History  
Original issue  
Issue date: 1 8-SEP-2015  
Summary of Changes: n/a 
 
Amendment 001 
Issue Date :  05 -FEB-2016 
Summary of Changes : 
Based on recommendations from institutional reviews, the following changes were made:  
• Administrative changes  
o Updated footer and synopsis page with new protocol format and logo.  
o General spelling , capitalization, and formatting  changes, as needed . 
• Synopsis, Section 3.2  and Section  4: all references to Quality of Life Assessments by 
Functional Assessme nt of Cancer Therapy -Melanoma (FACT -M) and Brief Pain Inventory -
Short Form were deleted .  Sections 4.3, 8.7, and 8.8,  which were related to these 
assessments , were deleted and other sections were re -numbered as appropriate.  The QoL 
assessments were remove d from the protocol because it was decided that the low subject 
numbers would preclude a robust statistical analysis . 
• Section 3.1.12 : added reference to Section 3.2 . 
• Section 3.1.16 : Clarification was added to indicate that Post Study Fo llow -up will start after 
completion of the 100 -day On Study Follow -up. 
• Section 3.2, Study Flowchart:  
o A Final Assessment visit was added, and the assessments from On Study Follow -up 
were moved to the Final Assessment visit.   
o Clarification was provided that the On Study Foll ow-up will be assessed at 30, 70 and 
100 days a fter last study drug; AEs and pregnancy tests w ill be assessed as indicated by 
footnotes “a” and “e.”  
o 30, 70 and 100 day assessments were added to footnote “a.”  
o The following clarification was provided as foo tnote “d”: “Final Assessment will be 2 
weeks after last study drug, followed by On Study Follow -up and Post Study Follow -up. 
For those subjects who are continuing on nivolumab, Study Visits will continue Q2W ± 
3 days during treatment, followed by the Final Assessment Visit , On Study Follow -up, 
and Post Study Follow -up after last nivolumab treatment. Disease assessments by 
RECIST 1.1/ irRECIST will continue Q6W during the continued nivolumab treatment . 
o Clarification was added to indicate that Post Study Foll ow-up will start after completion 
of the 100 -day On Study Follow -up  
o Chemistry and hematology lab assessments were added for Weeks 14 and 16  
o Amylase and lipase assessments were added on the same days as other chemistry profile assessments  
o Free T3, Free T4 and TSH were separated from the routine chemistry profile and placed on a separate line.  
• Section 4.3.1 (previously 4.4.1)  and Section 8.6
 : Deleted “Whole exome sequencing for 
mutational load and neoantigens pre - and post -RT” from the list of correlative testing to be 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 39 of 70 done. In addition, it was clarified that the assays may include but may not  be limited to the 
list provided.  
• Section 5.1, Inclusion Criterion #1 was changed as follows (changes in bold): “ Histologic 
diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can be safe ly 
irradiated  and,  in the opinion of the radiation oncologist,  is of benefit to the subject  to 
irradiate ...” 
• Section 5.2, Exclusion Criterion #1 ( Any contraindications fo r ipilimumab (Yervoy®) or 
nivolumab (Opdivo®) as per the package inserts. ) was deleted ; remaining criteria were re -
numbered .  
• Section 5.3.1, #2: Added clarification  that washout period is 6 weeks for CTLA -4, PD -1, 
and/or PD -L1 antibodies and 12 weeks for other an tibodies . 
• Section 6.1, third paragraph was changed to allow for a time interval for the study drug 
administration time:  a) 60 -minute IV infusion was changed to “an IV infusion over 
approximately 60 minutes”; b) 9 0-minute IV infusion was changed to “an IV infusion over 
approximately 90 minutes.”  
• Section 6.1, next to last paragraph was changed as follows (changes in bold and  
underlined): “Dosing calculations should be based on body weight. If the subject’s weight 
on the day of dosing differs by > 10% from the weight used to calculate the dose, the dose 
must be recalculated. All doses should be rounded up or to the nearest mil ligram or as per 
local  institutional standard.”  
• Section 7.1.6: Changed Primary Sponsor Contact from Nerely A Cruz to Mary Macri.  
 
Amendment 2 
Issue Date :  06 -MAY-2016  
Summary of Changes : 
• Cover Page:  IND # was deleted, as this study is exempt. BMS reference number was added.  
• Section 3.1.15 : Enrollment period was changed from 1 year to 2 years; Length of Study  was 
change from 2 to 3 years.  
• Section 3.2, Flowchart:  
o “and pre -existing conditions” was deleted from the Medical History line.  
o Added Mg and LDH to list of chemistry assessments  
o Added the following statement to the Note in the footnote:  “ Standard of Care 
procedures m ay be used for eligibility assessments provided they meet the criteria 
specified in either the inclusion criteria or flowchart .” 
o Collection of serum or urine pregnancy tests was clarified in footnotes and flowchart. 
The following statement was added to foo tnote e: “Serum pregnancy test is done at 
screening, final assessment, and during On Study Follow -up; urine pregnancy test is 
done at all other visits , including during continued nivolumab treatment .”   
o Moved Week 14 urine pregnancy test to Week 12 . 
o The following clarification was added to fo otnote “d” (changes in bold):  “ Disease 
assessments by RECIST 1.1/ irRECIST will continue Q6W (starting 6 weeks after last 
disease assessment) during the continued nivolumab treatment. Subjects who do not 
continue tre atment with nivolumab after Week 18 do not need to have a repeat 
pregnancy test (if applicable) or disease assessment at the final assessment if the 
subject had these assessments at Week 18. ”  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 40 of 70 • Sections 4.3.1  and 8.6: deleted references to plasma miRNA levels and circulating cell free 
DNA quantity.  
• Section 5: added the following Note to Subject eligibility: “ Standard of Care procedures 
may be used for eligibility assessments provided they meet the criteria specified in either 
the inclus ion criteria or flowchart .”   
• Section 7.2.2: The following statement was added: “All subjects who sign an informed 
consent form , regardless of study procedures performed , will be assigned a screening 
number and have their data entered into the eCRF.”  
• Administrative changes: General spelling , grammar, capitalization, and formatting  changes, 
as needed . 
 
Amendment 3  
Issue Date:  10-NOV -2016  
Summary of Changes:  
• Synopsis  and Section 3.1 (Study Design) : Second sentence was modified (changes in bold): 
All su bjects will receive concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 
3 weeks for 4 doses, followed by n ivolumab monotherapy ( 3 mg/kg  240 mg) every 2 weeks.  
RATIONALE : monotherapy dose for continuing nivolumab was changed from 3 mg/kg to 
fixed dose of 240 mg  according current BMS prescribing information.  
• Section 3.1 (Study Design) and Section  3.1.9 (Dose -limiting toxicity) : The following note was 
added to Cohort A: “ Note: Grade 3 or 4 amylase or lipase abnormalities that are not 
associated with clinical symptoms will not be included in the Cohort A safety assessment 
described above.”  A refere nce to this note was provided in the Synopsis and in Section 
3.1.6 (Sample Size and Statistical Considerations).  
RATIONALE : amylase and lipase can increase to Grades 3/4 without serious issues (e.g., 
pancreatitis) being diagnosed.  
• Section 3.1.7 ( Treatment Arms and Treatment Schema): The monotherapy dose for 
continuing nivolumab was changed from 3 mg/kg to fixed dose of 240 mg as indicated above .  Footnote b was modified (changes in bold):  Administered once every 3 weeks for 4 
doses (at 1 mg/kg)  and then 2 40 mg  once every 2 weeks.  See Section 6.1 for order of 
infusion
. 
• Section 3.1.8 (Dosing Adjustments Delays and Discontinuations) and Section 8.5.6 
(Radiotherapy timing and dose fractionation): the following statement was added: “Dose 
modifications for radiotherapy as a result of toxicity are  allowed per the Investigator’s 
assessment.”  
• Section 3.2 (Flowchart): For the On Study Follow -up visits, the following windows were 
added  (changes in bold) : 30 (±4), 70 (±4) and 100 -107 days after last study drug . 
• Section 3.2 (Flowchart): Footnote f was added to clarify the dosing for nivolumab and ipilimumab: “ All subjects will receive concurrent nivolumab (1 mg/kg) followed by 
ipilimumab (3 mg/kg) on the same day every 3  weeks for 4 doses, then followed by 
nivolumab monotherapy (240 mg) every 2 weeks.  Radiotherapy will be initiated after the 
first dose and before the second dose of immunotherapy
.” 
• Section 5.1 ( Inclusion Criteria):  
o #3 was changed as follows (6 weeks changed to 4 weeks): Any number of prior therapies 
(including none).  For subjects who have received prior systemic treatment with CTLA -4, 
PD-1, and/or PD-L1 therapy, the last monoclonal antibody administration should be no 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 41 of 70 less than 6 4 weeks prior to start of this protocol therapy and all prior side effects must 
have resolved to grade 1 or less by the time of the start of this protocol therapy.  
o #4 was change d FROM : “Subject s must have completed chemotherapy, targeted 
therapy, investigational therapy, other immunotherapy, prior RT , or major surgery 
(requiring general anesthesia) at least 28 days before administration of the first dose of 
study drug(s) . Subject s undergoing minor surgical procedures and biopsies that do not 
require general anesthesia may begin receiving study therapy if sufficiently recovered as determined by the treating investigator. Clinically significant toxicity experienced during any prior therapy must be resolved or stabilized before the first dose of study drug(s) .”   
TO:  
“Subject s must have : 
• Completed investigational therapy, other immunotherapy,  or prior RT at least 28 
days before administration of the first dose of study drug(s)  
• Completed chemotherapy or targeted therapy  at least 14  days before 
administration of the first dose of study drug(s)  
• Sufficiently recovered from prior surgery as determined by the t reating 
Investigator.  
Clinically significant toxicity or pharmacodynamic effects experienced during any prior 
therapy must be resolved or stabilized before the first dose of study drug(s) .” 
• Section 6.1 (Ipilimumab and Nivolumab): the following paragraph was modified (changes in bold):  “When study drugs (ipilimumab or nivolumab) are to be administered on the same 
day, separate infusion bags and filters must be used for each infusion. It is recommended 
that nivolumab be administered first, as an IV infusion over approximately 60 minutes (or 
30 minutes ; see note ), followed by ipilimumab administered as an IV infusion over 
approximately 90 minutes (or 30 minutes)  that starts approximately 30 minutes after 
completion of the nivolumab infusion. Note: an infusion time of 30 minutes may also be used for each of the drug  infusions  (i.e., 30-minute infusion for nivolumab→30 -minute 
interval→30 -minute infusion for ipilimumab)  as described by Mar tin-Algarra, et al. (46)”  
RATIONALE :  the reduced infusion ti mes are based on recommendations from BMS and 
data presented at ESMO 2016  by Martin -Algarra , et al.  (46)  
 
Amendment 4 
Issue Date:  10-MAY -2017  
Summary of Changes:  
• Synopsis  and Section 3.1.6 (Sample Size and Statistical Considerations) : for paragraph 2, 
sentence 2, the following clarification was added (changes in bold): “ (see exception in 
Section 3.1, i.e., asymptomatic amylase and lipase abnormalities are not included ).  
• Section 3.1.9 (DLT): the following statement was added to provide clarification for the safety evaluation period: “ The Cohort A assessment period for this evaluation will include 
the first 2 cycles of treatment, up to and including the pre -dose safety assessments 
scheduled for Cycle 3  (see Section 4.1.2).”  
• Section 3.1.11 (Subject Evaluability and Replacement) : clarification was provided to 
indicated that the AEs in points 1 and 2 are “related” AEs.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 42 of 70 • Section 3.2, Flowchart:  
o The disease assessment  frequency after Week 18 was changed from Q6W to Q12W  
(specifically, ” Week 24, then Q12W ± 7 days) , based on Investigator input that Q6W 
scanning is too frequent for patients who have had a response or stable disease after 
their first 24 weeks on study.  
o Footnote d was changed to align with the change for disease assessment (changes in 
bold): “Final Assessment will be 2 we eks (± 3 days) after last study drug, followed by On 
Study Follow -up and  Post Study Follow -up. A repeat disease assessment scan is not 
required at the final assessment visit if a scan was done within the previous 6 weeks 
before the final assessment visit. Subjects who do not continue treatment with 
nivolumab after Week 18 do not need to have a repeat pregnancy test (if applicable) at the final assessment if the subject had this assessment at Week 18.    For those 
subjects who are continuing on nivolumab, Study Visits will continue Q2W ± 3 days during treatment, followed by the F inal Assessment Visit, On Study Follow -up, and Post 
Study Follow -up after the last nivolumab treatment.  Subjects continuing nivolumab 
monotherapy and subjects who complete study treatment as responders will have an additional scan (disease assessments by R ECIST 1.1/ irRECIST) at Week 24 and 
subsequent scans Q12W (± 7 days) until progression or start of alternate anti -cancer 
therapy.  Disease assessments by RECIST 1.1/ irRECIST will continue Q6W (starting 6 
weeks after last disease assessment) during the cont inued nivolumab treatment. 
Subjects who do not continue treatment with nivolumab after Week 18 do not need 
to have a repeat pregnancy test (if applicable) or disease assessment at the final 
assessment if the subject had these assessments at Week 18. ” 
o Post Study Follow -up frequency was changed for Q24W to Q12W to align with disease 
assessment frequency.  This was also changed i n Section 3.1.16 . 
o Added “Electrocardiogram (baseline and as clinically indicated)” to allow for a baseline for cardiac monitoring.  
o Study week row was clarified to indicate week vs cycle  (changes in bold):  
Study Week   Week 1 
(Cycle 1)  Week 4 
(Cycle 2)  Week 7 
(Cycle 3)  Week  10 
(Cycle 4)  Week  
12 Week 
14 Week  
16 Week   
18 
o Final Assessment column header was clarified (changes in bold): “Final Assessment and 
Ongoing Treatment / Assessmentsd” 
• Section 4.1.2 (Subject Evaluation and Statistics): Updated PP Population to clarify 
evaluation period. (changes in bold): “The Per-Protocol ( PP) Population for safety and 
tolerability is defined as all subjects who received at least 75% of the scheduled doses of study drugs and RT over the first 2 cycles, as well as, respective safety assessments  (up to 
and including the pre -dose assessments scheduled for Cycle 3)  without ma jor protocol 
violation s over the entire Cohort A concurrent  ipilimumab and nivolumab  assessment 
period (as defined in Section 
3.1.9 ).” 
• Section 5.3.1 (Non -permitted Concomitant Therapies): made corrections to align with 
language in Section 5.1 (Inclusion Criteria) #4 (changes in bold): “ Other non -study cancer 
therapy (chemotherapy or immunotherapy) , with a wash -out period of 4 weeks ( 2 weeks 
for chemotherapy , 6 weeks for nitrosoureas and CTLA -4, PD -1, and/or PD -L1 antibodies  
and 12 weeks for other  antibodies  other than CTLA -4, PD -1, and/or PD -L1 antibodies ) prior 
to Day  1.” 
 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 43 of 70 Amendment 5 
Issue Date:  12-JUN-2018  
Summary of Changes:  
• For subjects who continue  nivolumab  treatment after Week 18, a dosing option of 480 mg 
every 4 weeks was added.  Rationale: this option was provided based on current dosing 
options that are available. This change was added to the following sections:  
o Synopsis, Section 3.1 (Study Design), and Section 3.1.7 (Treatment Arms and Schema), 
Table 1. “ Note: per Amendment 5, nivolumab monotherapy continuing after Week 18 
may be given as 480 mg every 4 weeks starting on Week 20, followed by Weeks 24, 28, 
etc.).”  
• Section 3.2 (Flowchart) : 
o Footnote c was updat ed to provide clarification and agreement with Inclusion criterion 
#2 (changes in bold):  “ Tumor biopsies are optional but are encouraged. Biopsies ar e 
prohibited from compromising the requirement for at least  one measurable lesion 
undergoing RT  and one measurable lesion not undergoing RT .” 
o Footnote d was updated to  (1) provide clarification  that subjects who have not 
progressed will also have an additional scan at Week 24 and subsequent scans Q12W (± 
7 days) until progression or start o f alternate anti- cancer therapy; and (2) to add 
information regarding the  480 mg  (every 4 weeks)  dosing after Week 18 for nivolumab 
(changes in bold ):  
Final Assessment  will be 2 weeks (± 3 days) after last study drug, followed by On Study 
Follow -up and Post Study Follow -up. A repeat disease assessment scan is not required at 
the final assessment visit if a scan was done within the previous 6 weeks before the final 
assessment visit. Subjects who do not continue treatment with nivolumab after Week 18 
do not need to have a repeat pregnancy test (if applicable) at the final assessment if the subject had this assessment at Week 18.   
For those subjects who are continuing on n ivolumab after Week 18 at 240 mg every 2 
weeks ±3 days , Study Visits will continue every 2 weeks ± 3 days during treatment, 
followed by the Final Assessment Visit, On Study Follow -up, and Post Study Follow -up after 
the last nivolumab treatment.  Per Amendm ent 5, nivolumab monotherapy continuing after Week 18 may be given as 
480 mg every 4 weeks 
±3 days, starting on Week 20, followed by Weeks 24, 28, etc.   
For those subjects who are continuing on nivolumab  after Week 18  at 480 mg every 4 
weeks ±3 days , Study  Visits will continue every 4 weeks ± 3 days during treatment, 
followed by the Final Assessment Visit, On Study Follow -up, and Post Study Follow -up 
after the last nivolumab treatment.  
Subjects continuing nivolumab monotherapy , and subjects who complete stu dy treatment 
as responders , and subjects who have not progressed (either in irradiated or non-
irradiated tumor burden)  will have an additional scan (disease assessments by RECIST 1.1/ 
irRECIST) at Week 24 and subsequent scans Q12W (± 7 days) until progress ion or start of 
alternate anti- cancer therapy.  
o Footnote e : the following note was added:  “For females of child -bearing potential who 
are continuing on nivolumab after Week 18 at 480 mg every 4 weeks, urine pregnancy 
tests may be done every 8 weeks .” 
o Footnote f was updated to provide clarification (changes in bold): “ All subjects will 
receive concurrent nivolumab (1 mg/kg) followed by ipili mumab (3 mg/kg) on the same 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 44 of 70 day every 3  weeks for 4 doses, then followed by nivolumab monotherapy (240 mg 
every 2 weeks ±3 days ). See footnote d for ongoing nivolumab monotherapy  after 
Week 18 . Radiotherapy will be initiated after the first dose and before the second dose 
of immunotherapy.  
o Footnote g was added to reflect current requirements for LDH and thyroid testin g; the 
change was added only for ongoing treatment period after Week 18  to allow for the 
core study to have consistent collection of data . 
• Section 5.1 , Exclusion Criterion # 14 was clarified (changes in bold): “ Any condition that, in 
the clinical judgment of the treating physician, is likely to interfere with the interpretability 
of the data or  prevent the subject from complying with any aspect of the protocol or that 
may put the subject at unacceptable risk. ” 
• Section 6.1.2 (Nivolumab Preparation and Administration). “ Additional information ” was 
added per instructions provided by BMS (added last  2 paragraphs).  
• Administrative changes: General spelling , grammar, capitalization, and formatting  changes, 
as needed . 
• Section 8.7 (Abbreviations) was updated.  
 
 
 
 
  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 45 of 70 8.2 Participating Study Sites, Investigators and Staff, Laboratories, and 
Sponsor Information  
This information is provided in the Clinical Study File . 
  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 46 of 70 8.3 Ipilimumab  and Nivolu mab Dose Delays and Adjustments  
No dose reductions or escalations are permitted . 
Criteria for Dose Delay  
Because of the potential for clinically meaningful immuno -oncology -related AEs requiring early 
recognition and prompt intervention, management algorithms have been developed for  the 
following suspected AEs : diarrhea/colitis; elevated creatinine; pneumonitis; elevated liver 
function tests  (LFTs) ; elevated TSH; ras h; and neurological AEs ( see Section 8.3.1 ). 
Dose delay criteria apply to  all drug -related AEs (regardless  of whether or not an  event is 
attributed to nivolumab, ipilimumab , or both). All study drugs must be delayed until criteria for 
resumption of treatment are met.  
Nivolumab and ipilimumab administration should be delayed for the following:  
• Any Grade ≥ 2 non -skin, drug- related AE, with the following exceptions:  
o Grade 2 drug- related fatigue or laboratory abnormalities do not require a treatment 
delay . 
• Any Grade 3 skin, drug- related AE. 
• Any Grade 3 drug- related laboratory abnormality, with the following exceptions for 
asymptomatic amylase or lipase, AST, ALT, or total bilirubin:  
o Grade 3 amylase or lipase abnormalities that are not associated with symptoms or 
clinical manifestations of pancreatitis do not require a dose delay. It is recommended t o 
consult with the Sponsor for Grade 3 amylase or lipase abnormalities.  
o If a subject has a baseline AST, ALT, or total bilirubin that is within normal limits, delay dosing for drug- related Grade ≥ 2 toxicity . 
o If a subject has baseline AST, ALT, or total bilirubin within the Grade 1 toxicity range, delay dosing for drug -related Grade ≥ 3 toxicity . 
• Any AE, laboratory abnormality, or intercurrent illness that , in the judgment of the 
investigator, warrants delaying the dose of study medication.  
Criteria to Resu me Treatment  
Subjects may resume treatment with study drug s when the drug- related AE(s) resolve to 
Grade  ≤ 1 or baseline value, with the following exceptions:  
• Subjects may resume treatment in the presence of Grade 2 fatigue.  
• Subjects who have not experienc ed a Grade 3 drug- related skin AE may resume treatment in 
the presence o f Grade 2 skin toxicity.  
• Subjects with baseline Grade 1 AST/ALT or total bilirubin who require dose delays for reasons other than a 2 -grade shift in AST/ALT or total bilirubin may resu me treatment in the 
presence of Grade 2 AST/ALT OR total bilirubin . 
• Subjects with combined Grade 2 AST/ALT AND total bilirubin values meeting discontinuation parameters should have treatment permanently discontinued . 
• Drug- related pulmonary toxicity, diarrhea, or colitis must have resolved to baseline before 
treatment is resumed . 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 47 of 70 • Drug- related endocrinopathies adequately controlled with only physiologic hormone 
replacement may resume treatment.  
If the criteria to resume treatment are met, the subject should restart treatment at the next 
scheduled time  point per protocol. However, if the treatment is delayed past the next scheduled 
time  point per protocol, the next scheduled time  point will be delayed until dosing resumes. 
Doses may not be skipp ed.  For ipilimumab, the intent is to administer all 4 doses if possible.  
If treatment is delayed for > 6 weeks, the subject must be permanently discontinued from study 
therapy, except as specified in the discontinuation criteria.  
Discontinuation Criteria  
Treatment should be permanently discontinued for the following:  
• Any Grade 2 drug- related uveitis or eye pain or blurred vision that does not respond to 
topical therapy and does not improve to Grade 1 severity within the re -treatment period  OR 
requires sys temic treatment.  
• Any Grade 3 non -skin, drug -related AE lasting > 7 days, with the following exceptions for 
drug- related laboratory abnormalities, uveitis, pneumonitis, bronchospasm, diarrhea, colitis, 
neurologic AE, hypersensitivity reactions, and infusion  reactions : 
o Grade 3 drug- related uveitis, pneumonitis, bronchospasm, diarrhea, colitis, neurologic 
adverse event, hypersensitivity reaction, or infusion reaction of any duration requires 
discontinuation . 
o Grade 3 drug- related laboratory abnormalities do not  require treatment discontinuation 
except those noted below:  
 Grade 3 drug- related thrombocytopenia > 7 days or associated with bleeding 
requires discontinuation . 
 Any drug- related LFT abnormality that meets the following criteria require s 
discontinuation:  
 AST or ALT > 8 x ULN . 
 Total bilirubin > 5 x ULN . 
 Concurrent AST or ALT > 3 x ULN and total bilirubin > 2 x ULN . 
• Any Grade 4 drug- related AE or laboratory abnormality, except for the following events 
which do not require discontinuation:  
o Isolated Grade 4 amylase or lipase abnormalities that are not associated with symptoms 
or clinical manifestations of pancreatitis.  
o Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with clinical sequelae and are corrected with s upplementation/appropriate management 
within 72 hours of their onset . 
• Any dosing interruption lasting > 6 weeks with the following exceptions:  
o Dosing interruptions to allow for prolonged steroid tapers to manage drug -related AEs 
are allowed. Prior to re -initiating treatment in a subject with a dosing interruption 
lasting > 6 weeks, the Investigator must be consulted. Tumor assessments should continue as per protocol even if dosing is interrupted . 
o Dosing interruptions > 6 weeks that occur for non -drug -relate d reasons may be allowed 
if approved by the Investigator. Prior to re -initiating treatment in a subject with a dosing 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 48 of 70 interruption lasting > 6 weeks, the Investigator must be consulted. Tumor assessments 
should continue as per protocol even if dosing is in terrupted . 
• Any AE, laboratory abnormality, or intercurrent illness that , in the judgment of the 
Investigator, presents a substantial clinical risk to the subject with continued nivolumab or 
ipilimumab dosing . 
Treatment of Nivolumab-  or Ipilimumab- related I nfusion Reactions  
Since nivolumab and ipilimumab contain only human immunoglobulin protein sequences, it is 
unlikely to be immunogenic and induce infusion or hypersensitivity reactions. However, if such a reaction were to occur, it might manifest with feve r, chills, rigors, headache, rash, pruritus , 
arthralgia, hypo - or hypertension, b ronchospasm, or other symptoms.  
All Grade 3 or 4 infusion reactions should be reported as an SAE if criteria are met. Infusion reactions should b e graded according to NCI CTCA E, Version 4.0 3 guidelines.  
Treatment recommendations are provided below and may be modified based on local treatment standards and guidelines as appropriate:  
For Grade 1 symptoms:  (Mild reaction; infusion interruption not indicated; intervention not 
indic ated)  
Remain at bedside and monitor subject until recovery from symptoms. The following prophylactic premedications are recommended for future infusions: diphenhydramine 50 mg (or equivalent) and/or paracetamol (acetaminophen) 325 to 1000 mg at least 30 minutes before 
additional nivolumab /ipilimumab  administrations.  
For Grade 2 symptoms:  (Moderate reaction ; requires therapy or infusion interruption but 
responds promptly to symptomatic treatment [e. g., ant ihistamines, non -steroidal 
anti-inflammatory drugs,  narcotics, corticosteroids, bronchodilators, IV fluids]; prophylactic 
medications indicated for 24 hours).  
Stop the nivolumab or ipilimumab infusion, begin an IV infusion of normal saline, and treat the subject with diphenhydramine 50 mg IV (or equivalent ) and/or paracetamol (acetaminophen) 
325 to 1000 mg; remain at bedside and monitor subject until resolution of symptoms. Corticosteroid or bronchodilator therapy may also be administered as appropriate. I f the 
infusion is interrupted, restart the infusion at 50% of the original infusion rate when symptoms resolve; if no further complications ensue after 30 minutes, the rate may be increased to 100% 
of the original infusion rate. Monitor subject closely. If symptoms recur then no further 
nivolumab or ipilimu mab will be administered at that visit. Administer diphenhydramine 50 mg 
IV, and remain at bedside and monitor the subject until resolution of symptoms. The amount of study drug infused must be recorded on the eCRF. The following prophylactic premedication s 
are recommended for future infusions: diphenhydramine 50 mg (or equivalent) and/or paracetamol (acetaminophen) 325 to 1000 mg  should be administered at least 30 minutes 
before additional nivolumab or ipilimumab administrations. If necessary, corticostero ids 
(recommended dose: up to 25 mg of IV hydrocortisone or equivalent) may be used.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 49 of 70 For Grade 3 or Grade 4 symptoms:  (Grade 3  [severe reaction;  prolonged (i.e., not rapidly 
responsive to symptomatic medication and/or brief interruption of infusion ); recurrence of 
symptoms following initial improvement; hospitalization indicated for other clinical sequelae 
(e.g., renal impairment, pulmonary infiltrates ). Grade 4  [life-threatening  reactions ; pressor or 
ventilatory support indicated ]). 
Immediately disc ontinue infusion of nivolumab or ipilimumab. Begin an IV infusion of normal 
saline, and treat the subject as follows. Recommend bronchodilators, epinephrine 0.2 to 1 mg of a 1:1,000 solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 s olution 
injected slowly for IV administration, and/or diphenhydramine 50 mg IV with methylprednisolone 100 mg IV (or equivalent), as needed. Subject should be monitored until the investigator is comfortable that the symptoms will not recur. Nivolumab or ip ilimumab will be 
permanently discontinued. Investigators should follow their institutional guidelines for the treatment of anaphylaxis. Remain at bedside and monitor subject until recovery from symptoms. In the case of late- occurring hypersensitivity sympt oms (e .g., appearance of a 
localized or generalized pruritus  within 1 week after treatment), symptomatic treatment may b e 
given (e .g., oral antihistamine  or corticosteroids).  
For subjects who are expected to require more than 4 weeks of corticosteroids or other immunosuppressants to manage AEs, the following recommendations should be considered.  
• Administer antimicrobial/antifungal prophylaxis per institutional guidelines to prevent 
opportunistic infections such as Pneumocystis jiroveci and fungal infections . 
• Early consultation with an infectious disease specialist should be considered. Depending on 
the presentation, consultation with a pulmonologist for bronchoscopy or a gastroenterologist for endoscopy may also be appropriate.  
• In subjects  who develop recurr ent AEs in the setting of ongoing or prior immunosuppressant 
use, an opportunistic infection should be considered in the differential diagnosis.  
8.3.1  Management Algorithms for Adverse Events Associated with 
Immuno -oncology Agents  
Please refer to the most curren t version of the nivolumab IB for current recommendations for 
management of a specific Adverse Event of interest.  The following m anagement algorithms are 
available in the  Appendix of the  IB: 
• GI AE Management  
• Renal  AE Management  
• Pulmonary  AE Management  
• Hepatic  AE Management  
• Endocrinopathy  Management  
• Skin AE Management  
• Neurological AE  Management  
 
 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 50 of 70 8.4 RECIST 1.1 and irRECIST Guidelines  
The Response Evaluation Criteria in Solid Tumors (RECIST) guidelines were  revised in 2009 as 
RECIST 1.1. (47) These guidelines have been the widely accepted criteria to assess response and 
progre ssion in solid tumors ; however, limitations have been noted in the use of RECIST 1.1 for 
immunotherapy  trials. With immunotherapeutic agents, clinical trials have shown that complete 
response, partial response, or stable disease status can still be achieve d after an initial increase 
in overall tumor burden, and regression of initial lesions may occur despite development of new 
lesions.  The Immune -related Response Criteria (irRC) were developed to address the need for 
response criteria in an immunotherapy se tting. (13)  The main difference with irRC was that it 
considered the subject's total tumor burden  at each subsequent assessment and required 
confirmation of suspected disease progression with subsequent imaging, approximately four 
weeks later.  In addition, a greater number of lesions (10 vs. 5) were measured in a 
bidimensional manner instead of  unidimensionally  as in RECIST 1.1 .  In 2013, Nishino et al. 
demonstrated that immune -related response criteria using unidimensional measurements were 
highly concordant with the bidimensional results of irRC, but with less measurement 
variability. (48)  Based on t hese findings and in order to utilize both the established criteria of 
irRC and RECIST 1.1, the two systems have been adapted, modified, and combined into the 
Immune -related Response Evaluation Criteria in Solid Tumors (irRECIST) .(49)  The adapted 
irRECIST criteria are modifications to the irRC, incorporating the findings of Nishino et al. and the advantages of RECIST 1.1 while overcoming the shortcomings of each of the other guidelines .  
The guidelines for RECIST 1.1 are summarized below, followed by a summary for irRECIST.  
RECIST 1.1  
The following section outlines the RECIST 1.1 guidelines as published ( 47) and as summarized by 
National Cancer Institute for CTEP -involved clinical trials .   
I. Disease Parameters for RECIST 1.1  
Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST 1.1 criteria.  
Measurable disease .  Measurable lesions are defined as those that can be accurately measured 
in at least one dimension (longest diameter to be recorded) as > 20 mm b y chest x -ray, as >10 
mm with CT scan, or >10 mm with calipers by clinical exam.  All tumor measurements must be 
recorded in millimeters  (or decimal fractions of centimeters).  
Note:  Tumor lesions tha t are situated in a previously irradiated area might or might not be 
considered measurable.  If the investigator thinks it appropriate to include them, the conditions 
under which such lesions should be considered must be defined in the protocol . 
NOTE for irRECIST: During target lesion selection the radiologist will consider information on 
the anatomical sites of previous intervention (e.g. previous irradiation,  RF-ablation, TACE, 
surgery, etc.). Lesions undergoing prior intervention will not be selected as target lesions 
unless there has been a demonstration of progress in the lesion.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 51 of 70 Malignant lymph nodes.   To be considered pathologically enlarged and measurable, a lymph 
node must be >15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm).  At baseline and i n follow -up, only the short axis 
will be measured and followed.  
Non -measurable disease .  All other lesions (or sites of disease), including small lesions (longest 
diameter <10 mm or pathological lymph nodes with ≥ 10 to <15 mm short axis), are considered 
non-measurable disease.  Bone lesions, leptomeningeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by CT or MRI), are considered as non -measurable.  
Note:  Cys tic lesions that meet the criteria for radiographically defined simple cysts should not 
be considered as malignant lesions (neither measurable nor non -measurable) since they are, by 
definition, simple cysts.   ‘Cystic lesions’ thought to represent cystic metastases can be 
considered as measurable lesions, if they meet the definition of measurability described above. However, if non -cystic lesions are present in the same patient, these are preferred for selection 
as target lesions.  
NOTE for irRECIST:  
Lesions  that are partially cystic or necrotic can be selected as target lesions. The longest 
diameter of such a lesion will be added to the Total Measured Tumor Burden (TMTB) of all 
target lesions at baseline. If other lesions with a non- liquid/non- necrotic compo nent are 
present, those should be preferred.  
Brain lesions detected on brain scans can be considered as both target or non- target lesions 
depending on the protocol definition.  
Target lesions.   All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, representative of all involved organs, should be identified as target lesions  and recorded 
and measured at baseline.  Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative  of all involved organs, but in addition should be 
those that lend themselves to reproducible repeated measurements.  It may be the case that, on occasion, the largest lesion does not lend itself to reproducible measurement in which circumstance the next l argest lesion which can be measured reproducibly should be selected.  A 
sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the baseline sum diameters.  If lymph nodes  are to be 
included in the sum, then only the short axis is added into the sum.  The baseline sum diameters will be used as reference to further characterize any objective tumor regression in the 
measurable dimension of the disease.  
Non -target lesions .  All other lesions (or sites of disease) including any non -measureable as well 
as measurable lesions over and above the 5 target lesions should be identified a s non -target 
lesions and should also be recorded at baseline.  Measurements of these lesions are not  
required, but the presence, absence, or in rare cases unequivocal progression of each should be 
noted throughout follow -up.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 52 of 70 II. Methods for Evaluation of Measurable Disease  
All measurements should be taken and recorded in metric notation using a ruler or calipers.  All 
baseline evaluations should be performed as closely as possible to the beginning of treatment and never more than 4 weeks before the beginning of the treatment.  
The same method of assessment and the same technique should be used to character ize each 
identified and reported lesion at baseline and during follow -up. Imaging- based evaluation is 
preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be imaged but are assessable by clinical exam.  
Clinical lesions :  Clinical lesions will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and ≥10 mm diameter as assessed using calipers 
(e.g., skin nodules).  In the case of skin lesions, documentation by color photogr aphy, including a 
ruler to estimate the size of the lesion, is recommended.  
Chest x- ray:  Lesions on chest x -ray are acceptable as measurable lesions when they are clearly 
defined and surrounded by aerated lung.  However, CT is preferable.  
Conventional C T and MRI:   This guideline has defined measurability of lesions on CT scan based 
on the assumption that CT slice thickness is 5 mm or less.  If CT scans have slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.  MRI is also acceptable in certain situations (e.g. for body scans).   
Use of MRI remains a complex issue.  MRI has excellent contrast, spatial, and temporal resolution; however, there are many image acquisition variables involved in MRI, wh ich greatly 
impact image quality, lesion conspicuity, and measurement.  Furthermore, the availability of MRI is variable globally.  As with CT, if an MRI is performed, the technical specifications of the scanning sequences used should be optimized for the evaluation of the type and site of disease.  
Furthermore, as with CT, the modality used at follow -up should be the same as was used at 
baseline and the lesions should be measured/assessed on the same pulse sequence.  It is beyond the scope of the RECIST gu idelines to prescribe specific MRI pulse sequence parameters 
for all scanners, body parts, and diseases.  Ideally, the same type of scanner should be used and the image acquisition protocol should be followed as closely as possible to prior scans.  Body scans should be performed with breath -hold scanning techniques, if possible.  
PET-CT:  At present, the low dose or attenuation correction CT portion of a combined PET- CT is 
not always of optimal diagnostic CT quality for use with RECIST measurements.  However , if the 
site can document that the CT performed as part of a PET- CT is of identical diagnostic quality to 
a diagnostic CT (with IV and oral contrast), then the CT portion of the PET -CT can be used for 
RECIST measurements and can be used interchangeably wi th conventional CT in accurately 
measuring cancer lesions over time.  Note, however, that the PET portion of the CT introduces additional data which may bias an investigator if it is not routinely or serially performed.   
Ultrasound:   Ultrasound is not use ful in assessment of lesion size and should not be used as a 
method of measurement.  Ultrasound examinations cannot be reproduced in their entirety for independent review at a later date and, because they are operator dependent, it cannot be 
guaranteed tha t the same technique and measurements will be taken from one assessment to 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 53 of 70 the next.  If new lesions are identified by ultrasound in the course of the study, confirmation by 
CT or MRI is advised.  If there is concern about radiation exposure at CT, MRI may  be used 
instead of CT in selected instances.  
Endoscopy, Laparoscopy:   The utilization of these techniques for objective tumor evaluation is 
not advised.  However, such techniques may be useful to confirm complete pathological response when biopsies are ob tained or to determine relapse in trials where recurrence 
following complete response (CR) or surgical resection is an endpoint.  
Tumor markers:   Tumor markers alone cannot be used to assess response.  If markers are 
initially above the upper normal limit, they must normalize for a patient to be considered in 
complete clinical response.  Specific guidelines for both CA -125 response (in recurrent ovarian 
cancer) and PSA response (in recurrent prostate cancer) have been published .(50-52)  In 
addition, the Gynecologic Cancer Intergroup has developed CA -125 progression criteria which 
are to be integrated with objective tumor assessment for use in first -line trials in ovarian 
cancer .(53)  
Cytology, Histology:   These techniques can be used to differentiate between partial responses 
(PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor types, such as germ cell tumors, where known residual benign tumors can remain).  
The cytological confirmation of the neoplastic origin of any effusion that appears or worsens during treatment when the measurable tumor has met criteria for response or stable disease is mandatory to differentiate between response or stable disease (an effusion may be a side effect of the treatment) a nd progressive disease.  
FDG -PET:   While FDG- PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG- PET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease).  New lesions on the basis of 
FDG -PET imaging can be identified according to the following algorithm:  
a) Negative FDG -PET at baseline, with a positive FDG- PET at follow -up is a sign of PD based 
on a new lesion.  
b) No FDG -PET at baseline and a positive FDG- PET at  follow -up:  If the positive FDG -PET at 
follow -up corresponds to a new site of disease confirmed by CT, this is PD.  If the 
positive FDG- PET at follow -up is not confirmed as a new site of disease on CT, additional 
follow -up CT scans are needed to determine  if there is truly progression occurring at 
that site (if so, the date of PD will be the date of the initial abnormal FDG- PET scan).  If 
the positive FDG -PET at follow -up corresponds to a pre -existing site of disease on CT 
that is not progressing on the ba sis of the anatomic images, this is not PD.  
c) FDG -PET may be used to upgrade a response to a CR in a manner similar to a biopsy in 
cases where a residual radiographic abnormality is thought to represent fibrosis or 
scarring.  The use of FDG- PET in this circu mstance should be prospectively described in 
the protocol and supported by disease -specific medical literature for the indication.  
However, it must be acknowledged that both approaches may lead to false positive CR 
due to limitations of FDG -PET and biopsy  resolution/sensitivity.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 54 of 70 Note:  A ‘positive’ FDG -PET scan lesion means one which is FDG avid with an uptake greater than 
twice that of the surrounding tissue on the attenuation corrected image.  
III. Response Criteria for RECIST 1.1  
A. Evaluation of Target Lesions  
Complete Response (CR) :  Disappearance of all target lesions.  Any pathological lymph nodes 
(whether target or non -target) must have reduction in short axis to <10 mm.    
Partial Response (PR) :  At least a 30% decrease in the sum of the diameters of target lesions, 
taking as reference the baseline sum diameters  
Progressive Disease (PD) :  At least a 20% increase in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study).  In addition to the relative increase of 20%, the sum must also demonstrate 
an absolute increase of at least 5 mm.  (Note:  the appearance of one or more new lesions is also considered progressions).  
Stable Disease (SD) :  Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study  
B. Evaluation of Non- Target Lesions  
Complete Response (CR) :  Disappearance of all non -target lesions and normalizat ion of tumor 
marker level.  All lymph nodes must be non -pathological in size (<10 mm short axis)  
Note:  If tumor markers are initially above the upper normal limit, they must normalize for a patient to be considered in complete clinical response.  
Non -CR/No n-PD:  Persistence of one or more non -target lesion(s) and/or maintenance of tumor 
marker level above the normal limits  
Progressive Disease (PD) :  Appearance of one or more new lesions and/or unequivocal 
progression of existing non -target lesions.  Unequiv ocal progression should not normally trump 
target lesion status.  It must be representative of overall disease status change, not a single lesion increase.   
Although a clear progression of “non -target” lesions only is exceptional, the opinion of the 
treat ing physician should prevail in such circumstances, and the progression status should be 
confirmed at a later time by the review panel (or Principal Investigator).  
C. Evaluation of Best Overall Response  
The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest 
measurements recorded since the treatment started).  The patient's best response assignment 
will depend on the achievement of bot h measurement  and confirmation criteria.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 55 of 70 1. For Patients with Measurable Disease (i.e., Target Disease)  
Target 
Lesions  Non -Target Lesions  New 
Lesions  Overall 
Response  Best Overall Response when 
Confirmation is Required*  
CR CR No CR >4 wks. Confirmation**  
CR Non -CR/Non -PD No PR 
>4 wks. Confirmation**  CR Not evaluated  No PR 
PR Non -CR/Non -PD/not evaluated  No PR 
SD Non -CR/Non -PD/not evaluated  No SD documented at least once >4 
wks. from baseline**  
PD Any Yes or No  PD 
no prior SD, PR or CR  Any PD***  Yes or No  PD 
Any Any Yes PD 
*      See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.  
**    Only for non- randomized trials with response as primary endpoint.  
***  In exceptional circumstances, unequivocal progression in non -target lesions may be accepted as disease 
progression.  
Note:  Patients with a global deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression at that time should b e reported as “ symptomatic 
deterioration.”   Every effort should be made to document the objective progression even after 
discontinuation of treatment.  
 
2. For Patients with Non- Measurable Disease (i.e., Non- Target Disease)  
Non -Target Lesions  New Lesions  Overall Response  
CR No CR 
Non -CR/non -PD No Non -CR/non -PD* 
Not all evaluated  No not evaluated  
Unequivocal PD  Yes or No  PD 
Any Yes PD 
* ‘Non -CR/non -PD’ is preferred over ‘stable disease’ for non -target disease since SD is increasingly used as an end -
point for assessment of efficacy in some trials so to assign this category when no lesions can be measured is not 
advised.  
 
D. Duration of Response  
Duration of overall response :  The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date that 
recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recor ded since the treatment started).  
The duration of overall CR is measured from the time measurement criteria are first met for CR until the first date that progressive disease is objectively documented.  
Duration of stable disease :  Stable disease is measure d from the start of the treatment until the 
criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, including the baseline measurements. 
  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 56 of 70 irRECIST 
Immune -related RECIST (irRECIST) guideline s according to Bohnsack et al. ( 49) are presented 
below.  
I. Baseline Assessments in irRECIST  
In irRECIST, baseline  assessment and measurement of measurable/non -measurable and 
target/non -target lesions and lymph nodes are in line with RECIST 1.1.  One new definition is 
added: If a subject has no measurable and no non -measurable disease at baseline the radiologist 
will assign ‘No Disease’ (irND) as the overall tumor assessment for any available follow -up time 
points unless new measurable lesions are identified and contribute to the total measured tumor 
burden ( TMTB ).  irND is a valid assessment in studies with adjuvant s etting where the protocol 
and study design allow the inclusion of subjects with no visible disease  
II Follow -up Assessments  in irRECIST  
A. Follow -up recording of target and new measurable lesions  
A key difference in irRECIST is that the appearance new lesions do es not automatically 
indicate progression .  Instead, all measured lesions (baseline -selected target lesions and new 
measurable lesions) are combined into the total measured tumor burden (TMTB)  at follow up.   
Baseline -selected t arget lesions and new measurable lesions are  NOT assessed separately. 
Measurements of those lesions ar e combined into the TMTB, and one combined assessment 
provided.  
In order to be selected as new measurable lesions  (≤ 2 lesions per organ, ≤ 5 lesions total, per 
time point ), new lesions must meet criteria as defined for baseline target lesion selection and 
meet the same minimum size requirements of 10 mm in long diameter and minimum 15 mm in short axis for new measurable lymph nodes. New measura ble lesions should be prioritized 
according to size, and the largest lesions elected as new measured lesions.  
B. Follow -up non -target assessment  
RECIST 1.1 definitions for assessment of non -target lesions apply.  The response of non -target 
lesions primarily contributes to the overall response assessments of irCR and irNon -CR/Non -PD 
(irNN). Non -target lesions do not affect irPR and irSD assessments. Only a massive and 
unequivocal worsening of non -target lesions alone, even without progress in the TMTB is 
indic ative of irPD .  In alignment with RECIST 1.1, baseline selected non -target lesions can never 
convert to measurable lesions, not even if they increase in size at subsequent time points and 
become measurable. Only true new lesions can be measured and contribute to the TMTB
. 
C. Follow -up for New Non -Measurable Lesions  
All new lesions not selected as new measurable lesions are considered new non -measurable 
lesions and are followed qualitatively. Only a massive and unequivocal progression of new non -
measurable lesions leads to an overall assessment of irPD for the time  point. Persisting new 
non-measurable lesions prevent irCR.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 57 of 70 III Overall Assessments for irRECIST  
The irRECIST overall tumor assessment is based on TMTB of measured target and new lesions, 
non-target lesion assessment and new non- measurable lesions . 
At baseline, the sum of the longest diameters (SumD) of all target lesions  (up to 2 lesions per 
organ, up to total 5 lesions) is  measured.   At each  subsequent tumor assessment  (TA), the SumD 
of the target lesions and of  new, measurable lesions  (up to 2 new lesions per organ, total 5 new 
lesions) are added  together to provide the total measurable tumor burden (TMTB) . 
Overall Assessments by irRECIST  
Complete Response 
(irCR)  Complete disappearance of all measurable and non- measurable lesions. Lymph 
nodes must decrease to < 10 mm in short axis.  
Partial Response 
(irPR)  Decrease of ≥ 30% in TMTB relative to baseline, non -target lesions are irNN, and 
no unequivocal progression of new non- measurable lesions  
• If new measurable lesions appear in subjects with no target lesions at 
baseline , irPD will be assessed. That irPD time  point will be considered a new 
baseline, and all subsequent time points will be compared to it for response assessment. irPR is possible if the TMTB of new measurable lesions decreases 
by ≥ 30% compared to the first irPD documentation  
• irRECIST can be used  in the adjuvant setting , in subjects with no visible 
disease on CT/MRI scans. The appearance of new measurable lesion(s) 
automatically leads to an increase in TMTB by 100% and leads to irPD. These 
subjects can achieve a response if the TMTB decreases at follow -up, as a sign 
of delayed response.  
• Based on the above, sponsors may consider enrolling subjects with no 
measurable disease and/or no visible disease in studies with response related 
endpoints . 
Stable Disease (irSD)  Failure to meet criteria for irCR or irPR in the absence of irPD 
Progressive Disease (irPD)  Minimum 20% increase and minimum 5 mm absolute increase in TMTB compared 
to nadir, or irPD for non -target or new non -measurable lesions. Confirmation of 
progressio n is recommended minimum 4 weeks after the first irPD assessment. An 
irPD confirmation scan may be recommended for subjects with a minimal TMTB 
%-increase over 20% and especially during the flare time -window of the first 12 
weeks of treatment, depending on  the compound efficacy expectations, to 
account for expected delayed response.  
• In irRECIST a substantial and unequivocal increase of non- target lesions  is 
indicative of progression.  
• IrPD may be assigned for a subject with multiple new non -measurable lesion s 
if they are considered to be a sign of unequivocal massive worsening  
Other  irNE:  used in exceptional cases where insufficient data exist.  
irND:  in adjuvant setting when no disease is detected  
irNN:  no target disease was identified at baseline, and at follow- up the subject 
fails to meet criteria for irCR or irPD 
 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 58 of 70 8.5 Recommended Guidelines for Radiation Therapy  
8.5.1  Target selection for radiation therapy  
The target for radiation therapy will be selected at the discretion of the protocol investigators.   
The target should not have been previously irradiated.   
In subject s that have had prior radiotherapy, treatment should not be carried out if the target is  
within 3 cm of the organ below (and criteria in parentheses  are met):  
Lung (prior v20 ≥25%)  
Spinal cord (prior dose >40 Gy within 3 cm of target)  
Brain, Globe, Optic nerves, Brainstem (prior dose >50 Gy within 3 cm of target)  
Brachial plexus (prior dose > 50 Gy within 3 cm of target)  
Bowel and stomach (prior dose >40 Gy within 3 cm of target)  
 
The target should be one that is not exclusively within bone ( i.e., a bone metastasis with no 
extraosseous soft tissue component), and therefore cannot be assessed fo r radiographic 
response by protocol -defined criteria.   
Priority should be given to irradiating symptomatic metastases.   
If multiple symptomatic targets are present, the largest target that can safely be irradiated 
should be chosen.   
More than one target  can be irradiated, but at least one site of measurable disease must be not 
be irradiated for response assessment purposes (see protocol).  
The radiotherapy target should be described categorically as one of the following:  
Lymph node  
Bone  
Skin Lung Liver  
Gastrointestinal tract  
Muscle  
Other  
 
The target for radiation therapy should be anatomically described (including laterality) in order to aid in radiographic response determination by the reference radiologist.  
 
8.5.2  Treatment position, immobilization, a nd simulation  
The treatment position will be comfortable enough to allow the patient to complete treatment, 
and will be chosen to preserve organ at risk constraints and provide adequate planning target volume coverage.  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 59 of 70 Immobilization devices will be used t o enhance reproducibility of setup.  
CT simulation will be carried out for all radiation therapy targets.   
The CT simulation should take place with the treatment position, with immobilization devices in 
place.  
The CT scan should include the entire treatmen t target, and 15 cm of the body superior and 
inferior to this.  This will ensure the entire anatomic structure will be included in the planning CT image for proper evaluation of the normal tissue dose -volume histogram, which is used as 
treatment planning c riteria.  
For targets within 5 cm of:  Must be included in simulation CT scan:  
Either lung  Thoracic inlet through 5 cm below the 
diaphragm/lung parenchyma  
Either kidney  Entire volume of bilateral kidney parenchyma  
Liver  Entire volume of liver  
Colon or rectum  Entire abdomen and pelvis (diaphragm dome 
through ischial tuberosities)  
 
The CT scan slice thickness should be no more than 3 mm.  
The use of motion assessment and compensation techniques (including, but not limited to 4D 
CT, slow CT, breath -hold t echniques, compression -belt, and respiratory gating) are permitted for 
moving targets, but not required.  
The use of contrast media for the CT scan is permitted, but not required.  
The use of adjunct imaging for simulation (PET, MRI) is permitted, but not re quired.  
8.5.3  Target delineation  
Target delineation will be carried out according to International Commission on Radiation Units (ICRU) guidelines 50 and 62.  
The gross tumor volume (GTV) is defined as the clinically and/or radiographically apparent site of melan oma chosen as a radiation therapy target.   
The clinical target volume (CTV) will be the same as the GTV.  
The internal target volume (ITV) will be determined based on motion assessment and compensation strategies applied (if any).  If no motion assessment is undertaken, then ITV will be the same as the CTV.  
The planning target volume (PTV) will be determined based on the anticipated setup 
uncertainty, machine tolerance, and intratreatment variation in CTV and/or ITV.  This is required to be betwe en 2 and 10 mm and need not be isotropic.   
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 60 of 70 8.5.4  Organ at risk dose (OAR) delineation and dose constraints  
The following OARs should be delineated on the CT simulation scan when they are within 10 cm 
of the PTV:   
Organ at risk (OAR)  Definition  
Skin Volume within 5 mm below skin surface  or “outer” contour  
Brain (not brainstem)   
Lens, left   
Lens, right   
Globe, left  
Globe, right   
Optic nerve, left   
Optic nerve, right   
Optic chiasm   
Brainstem (not medulla)   
Cochlea, left  http://www.ncbi.nlm.nih.gov/pubmed/15803007  
Cochlea, right  http://www.ncbi.nlm.nih.gov/pubmed/15803007  
Medulla and spinal cord  Bone limits of spinal canal until L2  
Spinal cord subvolume  http://www.ncbi.nlm.nih.gov/pubmed/23864755  
Larynx  http://www.ncbi.nlm.nih.gov/pubmed/24673866  
Esophagus  http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361  
Brachial plexus, left  http://www.ncbi.nlm.nih.gov/pubmed/18448267  
Brachial plexus, right  http://www.ncbi.nlm.nih.gov/pubmed/18448267  
Ribs, left  http://www.rto g.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361  
Ribs, right  http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361  
Trachea and mainstem bronchi  http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361  
*Lung, left  http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361  
*Lung, right  http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361  
Bronchioles  http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361  
Great vessels  http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361  
Pericardium/Heart  http://www.rtog.org/LinkClick.aspx?fileticket=VyMTDbz25wY%3d&tabid=361  
Stomach  http://www.ncbi.nlm.nih.gov/pubmed/24890348  
*Liver  http://www.ncbi.nlm.nih.gov/pubmed/24890348  
Common bile duct  http://www.ncbi.nlm.nih.gov/pubmed/24890348  
*Renal cortex, left   
*Renal cortex, right   
Renal hilum, left   
Renal hilum, right   
Ureter, left   
Ureter, right   
*Colon  http://www.ncbi.nlm.nih.gov/pubmed/24890348  
Duodenum  http://www.ncbi.nlm.nih.gov/pubmed/24890348  
Jejunum  http://www.ncbi.nlm.nih.gov/pubmed/24890348  
Ileum  http://www.ncbi.nlm.nih.gov/pubmed/24890348  
Cauda equine  Bone limits of spinal canal below L2  
Lumbrosacral plexus, left  http://www.ncbi.nlm.nih.gov/pubmed/22342301  
Lumbrosacral plexus, right  http://www.ncbi.nlm.nih.gov/pubmed/22342301  
*Rectum  http://www.ncbi.nlm.nih.gov/pubmed/22483697  
Bladder wall  http://www.ncbi.nlm.nih.gov/pubmed/22483697  
Penile bulb  http://www.ncbi.nlm.nih.gov/pubmed/22483697  
Femoral head, left  http://www.ncbi.nlm.nih.gov/pubmed/22483697  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 61 of 70 Organ at risk (OAR)  Definition  
Femoral head, right  http://www.ncbi.nlm.nih.gov/pubmed/22483697  
*Both  lungs, both kidneys , the liver, colon and rectum must be delineated in their entirety when included in the CT 
simulation scan.   
 
  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 62 of 70 OARs should be constrained so that a dose of 27 Gy  can be delivered in 3 fractions without 
exceeding limits below.   
OAR  Volume  Volume Max  Dose  Max Point Dose ** Endpoint (≥Grade 
3) 
Skin <10 cc  30 Gy 33 Gy  Ulceration  
Brain  <0.5 cc  18 Gy 23.1 Gy  Necrosis  
Lens (right or left)    12 Gy  Keratitis  
Globe (right or left)    16.2 Gy  Uveitis  
Optic nerves and chiasm 
(combined)  <0.2 cc  15.3 Gy  17.4 Gy  Neuritis  
Cochlea  (right or left)    17.1 Gy  Hearing loss  
Brainstem (not medulla)  <0.5 cc  18 Gy 23.1 Gy  Cranial neuropathy  
Medulla and spinal cord  <0.35 cc  
<1.2 cc  18 Gy 
12.3 Gy  21.9 Gy Myelitis  
Spinal cord subvolume  <10% of 
subvolume  18 Gy  21.9 Gy Myelitis  
Larynx    26.4 Gy  Laryngitis  
Esophagus*   <5 cc  17.7 Gy  25.2 Gy  Stenosis/fistula  
Brachial plexus  (right or 
left) <3 cc  20.4 Gy 24  Gy Neuropathy  
Ribs (each rib)  <1 cc 
<30 cc  28.8 Gy 
30 Gy  36.9 Gy Pain or fracture  
Trachea and main bronchi 
(combined) * <4 cc 15 Gy 30 Gy  Stenosis/fistula  
Lung (right and l eft 
combined ) 1500 cc  11.6 Gy  Basic lung function  
Lung (right and l eft 
combined ) 1000 cc  12.4 Gy  Pneumonitis  
Bronch ioles  <0.5 cc  18.9 Gy  23.1 Gy  Stenosis with 
atelectasis  
Great vessels  <10 cc  39 Gy  45 Gy  Aneurysm  
Pericardium/ Heart  <15 cc  24 Gy  30 Gy  Pericarditis  
Stomach  <10 cc 16.5 Gy 22.2 Gy Ulceration/fistula  
Liver  700 cc  19.2 Gy  Basic liver function  
Common b ile duct    36 Gy  Stenosis  
Renal cortex (right and l eft 
combined ) 200 cc  16 Gy  Basic renal function  
Renal hilum  (right or left)  <66% of 
volume  18.6 Gy   Malignant 
hypertension  
Ureter  (right or left)    40 Gy  Stenosis  
Colon*  <20 cc  24 Gy  28.2 Gy Colitis/fistula  
Duodenum*   <5 cc  
<10 cc  16.5 Gy 
11.4 Gy 22.2 Gy  Ulceration  
Jejunum and Ileum  
(combined) * <5 cc 17.7 Gy 25.2 Gy Enteritis/obstruction  
Cauda equine  <5 cc  21.9 Gy  24 Gy Neuritis  
Lumbros acral plexus  (right 
or left)  <5 cc  22.5 Gy  24 Gy  Neuropathy  
Rectum*  <20 cc 24 Gy 28.2 Gy Proctitis/fistula  
Bladder wall  <15 cc  16.8 Gy 28.2 Gy Cystitis/fistula  
Penile bulb  <3 cc  21.9 Gy 42 Gy  Impotence  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 63 of 70 Femoral he ads (right or left)  <10 cc  21.9 Gy 42 Gy  Necrosis  
*avoid circumferential irradiation  
**point defined as 0.035 cc or less  
8.5.5  Beam selection and geometry, planning technique and treatment delivery 
In general, beams should be chosen to preserve OAR constraints and provide adequate PTV 
dosing (D95 ≥95% of the prescription dose), while respecting mechanical constraints of 
equipment.  No minimum number of beams is necessary.   Coplanar and non -coplanar beams 
are permitted.  
Any form of external beam radiotherapy is acceptable (high energy photons, electrons, or protons), provided the dose is expressed in cobalt -Gy equivalent (CGyE) or Gy equivalent.  Beam 
energy should be chosen in consideration of penetration depth, neutron contamination, etc.  To 
accoun t for the radiobiologic effectiveness of electrons, investigators are encouraged to 
prescribe the radiation dose to the 90% isodose line that encompasses the PTV.   
Radiotherapy must be planned in 3 -dimensions, and dose -volume analyses are required to 
ensu re OAR constraints and PTV coverage is adequate.  For 3D conformal planning, both 
physical and dynamic wedges can be used.  Both MLC and block could be used for beam confinement when using photons.  
Planning and treatment delivery can be carried out using any technique (non -conformal, 
conformal, intensity -modulated, volume modulated arc, etc) using any mechanism of external 
beam radiation delivery (linear accelerator, CyberKnife™, etc).  
Use of tissue equivalent bolus to ensure adequate build -up is permitted for the treatment of 
superficial targets.  
Verification of accurate subject  positioning for treatment must occur through the generation 
and assessment of imaging (MV port films, kV images, cone beam CT, etc) or direct inspection of light fields (for electron beam therapy).  Conventional subject setup with skin tattoos or optical 
surface imaging can only be used as initial subject  alignment, but not final positioning.  
8.5.6  Radiotherapy timing and dose fract ionation  
Treatment will be initiated after the first dose of immunotherapy, but before the second dose of immunotherapy.  
Subject s receiving 27 Gy in 3 fractions should be scheduled to receive treatment on non -
consecutive weekdays, no more than 2 days/week,  over no more than 14 days.  Ideally, 
treatment will be given with 2 days between treatment (Monday/Thursday/Monday, Tuesday/Friday/Tuesday, Monday/Friday/Tuesday, or Tuesday/Friday/Wednesday schedule).  
Subject s receiving 30 Gy in 10 fractions should be sc heduled to receive treatment on 
consecutive weekdays, no more than 5 days/week, over no more than 14 days.  
Dose modifications for radiotherapy as a result of toxicity  are allowed per the Investigator’s 
assessment.   
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 64 of 70 8.6 Exploratory Assessment of Correlative Imm unologic Research  
Peripheral blood and optional tumor samples (when available) will be collected as outlined in 
Section 3.2 and banked for testing at the end of th e study.  Separate instructions will be 
provided regarding the processing, storage and testing of these samples.  Testing may include 
but may  not be limited to the following:  
• lymphocyte phenotype using markers such as ICOS, PD -1, and CD25  
• the quantities of myeloid derived suppressor cells (MDSCs), defined as CD14+HLA -DRlow 
cells  
• antibody and functional T cell responses to tumor associated antigens (i.e. NY -ESO-1) for 
relevant subject s  
• serum cytokine levels such as TNF -alpha, IFN -gamma, IL -1bet a, IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, IL- 12, and TGF -beta  
• Serum and plasma microparticle and exosome nanoFACS and proteomic profiles  
• T cell repertoire diversity in peripheral blood and tumor.  
Additional investigational methods will be used to characteriz e and measure components of the 
immune response based upon the latest available technology.  
  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 65 of 70 8.7 Abbreviations  
AE adverse event  
ALT alanine aminotransferase  
AST aspartate aminotransferase  
CRF Case report form  
CTCAE  Common Terminology Criteria for Adverse Events  
CTLA -4 Cytotoxic T lymphocyte -associated antigen 4  
DCR Disease control rate  
DLT dose -limiting t oxicity  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic Case Report Form  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
GMP  Good manufacturing practice  
HLA Human Leukocyte Antigen  
HNSCC  Head and neck squamous cell carcinoma  
IB Investigator Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmoni zation  
IL interleukin  
IND Investigational new drug  
irAE Immune -related adverse event  
irRC immune -related response criteria  
irRECIST  Immune -related Response Evaluation Criteria In Solid Tumors  
IV intravenous  
IRB Institutional Review Board  
LICR  Ludwig Institute for Cancer Research  
mAb  Monoclonal antibody  
MDSC  myeloid derived suppressor cells  
MTD  maximum t olerated dose 
NCI CTCAE  National Cancer Institute Common Terminology Criteria for Adverse  
Events  
NK Natural killer  
OAR  Organ at risk  
ORR  Objective Response Rate  
OS Overall survival  
PBMC  Peripheral blood mononuclear cell  
PD-1 Programmed d eath -1  
PD-L1 Programmed death ligand 1  
PFS Progression free survival  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 66 of 70 PK Pharmacokinetics  
Q2W  Every 2 weeks  
Q4W  Every 4 weeks  
Q6W  Every 6 weeks  
Q12W  Every 12 weeks  
RECIST  Response Evaluation Criteria in Solid Tumors  
RT Radiotherapy  
SAE Serious Adverse Event  
SD Standard Deviation  
TME  Tumor microenvironment  
TIL tumor -infiltrating lymphocyte  
ULN  Upper limit of normal  
 
  
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 67 of 70 9 References  
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA 
Cancer J Clin. 2011;61(2):69 -90. 
2. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III 
multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with 
metastatic melanoma. J Clin Oncol. 1999;17(9):2745 -51. 
3. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon 
alfa- 2b adjuvant therapy of high -risk resected cutane ous melanoma: the Eastern Cooperative 
Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7- 17. 
4. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U, et al. A pooled analysis 
of eastern cooperative oncology group and intergroup trials of adjuvant high -dose interferon for 
melanoma. Clin Cancer Res. 2004;10(5):1670 -7. 
5. Atkins M, Lotze M, Dutcher J, et al. High -dose recombinant interleukin 2 therapy for 
patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.  J 
Clin Oncol. 1999;17:2105 -16. 
6. Long G, Stroyakovskiy D, Gogas H, Levchenko E, et al. Dabrafenib and trametinib versus 
dabrafenib and placebo for Val600 BRAF -mutant melanoma: a multicentre, double -blind, phase 
3 randomised controlled trial. Lancet . 2015;Published Online: 30 May 2015.  
7. Yervoy™ (ipilimumab) [package insert] injection, for intravenous use. Initial U.S. 
Approval 2011. Bristol- Myers Squibb, Princeton, NJ. Available at: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf . Accessed 
December 3, 2011.  
8. Opdivo®  (nivolumab) [package insert] injection, for intravenous use, Initial US Approval 
2014. Bristol -Myers Squibb Company , Princeton, NJ; Available at: 
http://packageinserts.bms.com/pi/pi_opdivo.pdf . Accessed March 17, 2015.  
9. KEYTRUDA®  (pembrolizumab) [package insert] for injection fiu, Initial US Approval 2014 . 
Merck and Co, Whitehouse Station, NJ; Available at: 
http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf . Accessed 
November 3, 2014.  
10. Hodi F, O'Day S, McDermott D, et al.  Improved survival with ipilimumab in patients with 
metastatic melanoma. N Engl J Med 2010;363:711- 23. 
11. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus 
dacarbazine for previously untreated  metastatic melanoma. N Engl J Med. 2011;364(26):2517 -
26. 
12. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA -4 
blockade with ipilimumab: long -term follow -up of 177 patients with metastatic melanoma. Clin 
Cancer Res. 2012;18(7):2039 -47. 
13. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the 
evaluation of immune therapy activity in solid tumors: immune -related response criteria. Clin 
Cancer Res. 2009;15(23):7412 -20. 
14. Weber J, Thompson J, Hamid O,  et al.  A randomized, double -blind, placebo -controlled, 
phase II study comparing the tolerability and efficacy of ipilimumab administered with or 
without prophylactic budesonide in patients with unresectable stage III or IV melanoma.  Clin 
Cancer Res 2009 ;15:5591- 8. 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 68 of 70 15. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, 
activity, and immune correlates of anti- PD-1 antibody in cancer. N Engl J Med. 
2012;366(26):2443- 54. 
16. Topalian SL, Sznol M, McDermott DF, Kluger HM, C arvajal RD, Sharfman WH, et al. 
Survival, durable tumor remission, and long -term safety in patients with advanced melanoma 
receiving nivolumab. J Clin Oncol. 2014;32(10):1020 -30. 
17. Robert C, Long G, Brady B, et al. Nivolumab in previously untreated melan oma without 
BRAF mutation.  N Engl J Med. 2015;372:320 -30. 
18. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab 
plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122 -33. 
19. Postow MA, Chesney J, Pavlick A C, Robert C, Grossmann K, McDermott D, et al. 
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N Engl J Med. 
2015;372(21):2006- 17. 
20. Larkin J, Chiarion -Sileni V, Gonzalez R, Grob J, Cowey L, et al. Combined Nivolumab and 
Ipilimumab or Mo notherapy in Untreated Melanoma. N Engl J Med. 2015;May 31, 2015.  
21. Schild SE. Role of radiation therapy in the treatment of melanoma. Expert Rev 
Anticancer Ther. 2009;9(5):583 -6. 
22. Johanson CR, Harwood AR, Cummings BJ, Quirt I. 0 -7-21 radiotherapy in nodular 
melanoma. Cancer. 1983;51(2):226 -32. 
23. Huguenin P, Kieser S, Glanzmann C, Capaul R, Lutolf U. Radiotherapy for metastatic 
carcinomas of the kidney or melanomas: an analysis using palliative end points.  Int J Radiat 
Oncol Biol Phys 1998;41:401 -5. 
24. Overgaard J, von der Maase H, Overgaard M. A randomized study comparing two high -
dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int J 
Radiat Oncol Biol Phys. 1985;11(10):1837- 9. 
25. Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, et al. Fraction size in 
external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys. 
1991;20(3):429 -32. 
26. Olivier K, Schild S, Morris C, Brown P, Markovic S. A higher radiotherapy dose is 
associated with more durable palliation and longer survival in patients with metastatic 
melanoma.  Cancer. 2007;110:1791 -5. 
27. Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with 
fractionated radiation. Int J Radiat Oncol Biol Phys.  2012;83(4):1306 -10. 
28. Dewan M, Galloway A, Kawashima N, et al. Fractionated but not single -dose 
radiotherapy induces an immune -mediated abscopal effect when combined with anti -CTLA -4 
antibody.  Clin Cancer Res. 2009;15:5379 -88. 
29. Lee Y, Auh SL, Wang Y , Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative 
radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589- 95. 
30. Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab 
alone or in combination with radiotherapy in metastatic castration -resistant prostate cancer: 
results from an open -label, multicenter phase I/II study. Ann Oncol. 2013;24(7):1813 -21. 
31. Lugade A, Moran J, Gerber S, Rose R, Frelinger J, L ord E. Local radiation therapy of B16 
melanoma tumors increases the generation of tumor antigen -specific effector cells that traffic 
to the tumor. J Immunol. 2005;174:7516 -23. 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 69 of 70 32. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. 
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces 
successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259 -71. 
33. Chakravarty PK, Alfieri A, Thomas EK, Beri V, Tanaka KE, Vikram B, et al. Flt3 -ligand 
admi nistration after radiation therapy prolongs survival in a murine model of metastatic lung 
cancer. Cancer Res. 1999;59(24):6028 -32. 
34. Demaria S, Ng B, Devitt M, et al. Ionizing radiation inhibition of distant untreated tumors 
(abscopal effect) is immune m ediated. Int J Radiat Oncol Biol Phys 2004;58:862 -70. 
35. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, et al. Immune -
mediated inhibition of metastases after treatment with local radiation and CTLA -4 blockade in a 
mouse model of breast c ancer. Clin Cancer Res. 2005;11(2 Pt 1):728 -34. 
36. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti -PD-1 blockade and 
stereotactic radiation produce long -term survival in mice with intracranial gliomas. Int J Radiat 
Oncol Biol Phy s. 2013;86(2):343- 9. 
37. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and 
anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 
2014;124(2):687- 95. 
38. Twyman -Saint Victor C, Rech A,  Maity A, Rengan R, Pauken K, et al. Radiation and dual 
checkpoint blockade activate non -redundant immune mechanisms in cancer. Nature. 
2015;520(7547):373- 7. 
39. Formenti S, Friedman K, Chao K, et al . Abscopal response in irradiated patients: Results 
of a proof of principle trial.  Int J Radiat Oncol Biol Phys. 2008;72:S6 -S7. 
40. Seung S, Curti B, Crittenden M, Walker E, Coffey T, et al. Phase 1 study of stereotactic 
body radiotherapy and interleukin -2--tumor and immunological responses. Sci Transl Med. 
2012;4(137):137ra74.  
41. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic 
correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925 -
31. 
42. Golden EB, Demaria S, Schiff PB, Chachoua A, Formen ti SC. An abscopal response to 
radiation and ipilimumab in a patient with metastatic non -small cell lung cancer. Cancer 
Immunol Res. 2013;1(6):365 -72. 
43. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated 
with a systemic  anti-melanoma immune response. Int J Radiat Oncol Biol Phys. 2013;85(2):293 -
5. 
44. Sullivan R, Lawrence D, Wargo J, Oh K, Gonzalez R, Piris A. Case records of the 
Massachusetts General Hospital. Case 21 -2013. A 68 -year- old man with metastatic melanoma.  
N Engl J Med 2013;369:173- 83. 
45. Barker C, Postow MA, Khan S, Beal K, Parhar P, Yamada Y, et al. Concurrent radiotherapy 
and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res. 2013;1(2):92- 8. 
46. Martin -Algarra S, Haanen JB, Horak CE,  Bhatia S, Ribas A, Hwu WJ, et al. Safety of 
reduced infusion times for nivolumab plus ipilimumab and nivolumab alone in advanced melanoma. Eur Soc for Med Onc (ESMO). 2016:Poster 3386.  
47. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228 -47. 
 
 
CONFIDENTIAL  
SOP -C01-TMP -3 version 3  
LUD2015- 006 Protocol Amendment 5 (Final, 12-JUN-2018 ) Page 70 of 70 48. Nishino M, Giobbie -Hurder A, Gargano M, Suda M, Ramaiya N, Hodi F. Developing a 
common language for tumor response t o immunotherapy: immune -related response criteria 
using unidimensional measurements Clin Cancer Res 2013 2013;19(14):3936 -43. 
49. Bohnsack O, Ludajic K, Hoos A. Adaptation of the immune -related response criteria: 
irRECIST (ESMO 2014 Poster). Annals of Onco logy. 2014;25(S4):iv361- iv72.  
50. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade -Lauraine E, Jakobsen A, et al. Re: New 
guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer 
Inst. 2004;96(6):487- 8. 
51. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility 
and response guidelines for phase II clinical trials in androgen -independent prostate cancer: 
recommendations from the Prostate- Specific Antigen Working Group. J Clin Oncol. 
1999 ;17(11):3461- 7. 
52. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and 
end points of clinical trials for patients with progressive prostate cancer and castrate levels of 
testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin 
Oncol. 2008;26(7):1148- 59. 
53. Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade -Lauraine E, Parmar MK, et al. 
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. 
Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000;92(18):1534 -5. 
 